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Abstract
Inferring and explaining causal relationships is frequently one of the primary goals in
public health research. Randomized controlled trials (RCTs) are the gold standard for
establishing causal effects, but often RCTs are infeasible or unethical, and we must rely
on observational data for inference. Even in the case where RCTs can be conducted
causal inference is often difficult due to patient noncompliance. Statistical methods for
causal inference are needed in such cases. Although there exist well-established statisti-
cal causal inference methods, in this dissertation we develop methods for non-standard
scenarios. In Chapter 2, we consider treatment regimes for solid organ transplantation.
In Chapters 3 and 4, we consider estimating causal effects in RCTs in the presence of
noncompliance. In all cases, we develop novel weighted estimators that are similar to
inverse probability of compliance weighted estimators, but the weights are a ratio of
probabilities rather than an inverse probability. For solid organ transplantation, these
weights are needed so that our estimators have the desired interpretation, and in the
case of RCTs in the presence of noncompliance, these weights are needed so that our es-
timators actually correspond to a causal effect of interest when traditional assumptions
about noncompliance are not valid.
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Chapter 1
Introduction
Randomized controlled trials (RCTs) are the gold standard for establishing causation in
research with humans (Friedman and others, 2015). The randomization seeks to balance
both known and unknown participant characteristics that may influence the outcome.
Frequently, it is infeasible or unethical to randomize participants to a treatment, inter-
vention, or exposure. In these cases, we often rely on observational data for inference.
However, establishing the effect of a treatment with observational data is difficult due to
confounding (Greenland and others, 1999), that is, when participant characteristics are
associated with treatment assignment and with the outcome. An observed difference in
the effect of treatments may be due to the treatments themselves, to differences between
participant characteristics in the treatment groups, or both.
Even when data from RCTs are available, causal inference is often challenging due to
noncompliance, that is, participants not adhering to randomized treatment (Follmann,
2000; Glynn and others, 1994). In this scenario, although the assigned treatment is
randomized, the treatment actually received is not randomized. Analyzing data for
only compliant participants is problematic because compliers may differ systematically
from non-compliers, that is, compliance status is confounded (Lee and others, 1991).
Statistical methods for causal inference are needed in these cases and when attempt-
ing causal inference with observational data. Although the assumptions of the methods
are strong and frequently unverifiable, they nevertheless offer means to generate new
ideas for research and can be used to plan and conduct future randomized trials.
One popular strategy to address confounding with both observational data and with
1
2noncompliance in RCTs is inverse probability weighting (IPW) (Herna´n and Robins,
2006; Robins and others, 1994). The technique addresses confounding by modeling
treatment assignment as a function of patient characteristics. The model is used to
create a weighted “pseudo-population” for statistical inference. If all patient character-
istics affecting treatment assignment and the outcome are known and can be correctly
modeled, IPW allows for valid causal inference despite confounding in the un-weighted
data.
In this dissertation, we develop novel estimators of causal effects in non-standard sce-
narios. The estimators are similar to and were motivated by IPW estimators, but IPW
estimators are insufficient for these scenarios. The weights of my proposed estimators
are constructed as ratios of probabilities rather than as an inverses of probabilities.
In Chapter 2, we consider treatment strategies for organ transplantation, specifically
whether patients should avoid low-quality organs in the hopes that a better organ may
be offered in the future. In transplantation, RCTs are generally impractical, so we must
rely on observational registries for inference. To test a particular treatment strategy, we
use the outcomes of participants whose treatment history is consistent with a particular
treatment strategy, that is, they avoid organs that are low-quality. These patients
are said to be “compliant” with a particular treatment strategy. But in the case of
solid organ transplantation, cadaveric organs are allocated based on patient condition,
and so compliance is confounded. Inverse probability weighted estimators can be used
to correct for this confounding and to estimate the anticipated survival for following a
treatment strategy, but traditional IPW has an important limitation in this context: the
estimated anticipated survival is for a single random patient who adopts the treatment
strategy. We show in Chapter 2 that the anticipated survival can be different if the
entire population of participants adopts the strategy. We develop a class of estimators
to estimate the anticipated survival for either case. The weights are a ratio of the
probability of observing a patient’s treatment history in the counterfactual world where
some portion of patients adopt the strategy, to the probability of observing a patient’s
treatment history in the observed data.
In Chapter 3, We consider estimating causal effects in clinical trials with noncompli-
ance. Although there exist well-established methods for causal inference in the presence
of noncompliance, we argue that investigators frequently assume that compliance is
3measured without error. This is frequently an untenable assumption, particularly when
compliance is based on participants’ self-report. The method was strongly motivated
by an RCT testing the efficacy of very low nicotine content cigarettes on cigarettes
smoked per day. Although a substantial portion of patients reported strict compliance,
that is, reported smoking very low nicotine content cigarettes exclusively, biomarkers of
nicotine exposure were inconsistent with this claim for a large portion of patients, indi-
cating that compliance is being reported with error. Because existing causal inference
methods assume that compliance is measured without error, a causal estimator without
this assumption is needed to estimate causal effects with these data. We argue that
in this case compliance should be treated as an unobserved variable, and we propose a
novel estimator of the causal effect that weights participants according to the ratio of
the probability of compliance given the observed data to the probability of compliance
given the confounding variables. Although we treat compliance as an unobserved vari-
able, we show how to estimate the probability of compliance based only on the observed
data, resulting in a consistent and asymptotically normal estimator.
In Chapter 4, we develop more general causal estimators for use in clinical trials
where compliance is measured with error. Regression-based estimators are one alter-
native to IPW estimators. Provided that the confounders can be identified, and their
effect on the outcome correctly modeled, regression estimators can be used in place of
IPW for estimating causal effects. In addition, augmented estimators combine IPW
estimators with regression-based estimators. These estimators have the appealing prop-
erty that if either the regression model or the model for probability of compliance given
confounders is correct, the estimators are consistent even if the other model is misspec-
ified. But again, as with IPW estimators, these estimators traditionally have assumed
that compliance is measured without error. We propose regression-based estimators, an
augmented estimator, and extensions of the weighted estimators presented in Chapter
3 for use in cases where compliance is measured with error.
Chapter 2
Estimating Individual-Level and
Population-Level Causal Effects
of Organ Transplantation
Treatment Regimes
2.1 Chapter 2 Introduction
Determining an optimal rule or regime that dictates when a patient should start treat-
ment is an important step in personalizing medicine (Cain and others, 2010). However,
determining when a patient should undergo organ transplantation is challenging because
the availability and the quality of cadaveric organs on any particular day are random
and complex processes.
Because the number of people awaiting all solid organ transplants exceeds the num-
ber of available organs in the United States, the United Network for Organ Sharing
(UNOS) maintains a national list used to orderly offer available cadaveric organs to
potential recipients. For lung transplantation, for example, cadaveric lungs are offered
based on the blood type of the donor and recipient, location, and the lung allocation
score (LAS), a composite score of over a dozen patient characteristic that quantifies
both patients’ risk of death on the waiting list and their anticipated survival benefit
4
5from lung transplantation (Egan and Kotloff, 2005). Importantly, although the order
in which organs are offered is deterministic, who actually receives the offered organ is
random as patients may decline the offer (see Colvin-Adams and others (2012) for a
description of the lung allocation policy).
Poor quality of the organ is one reason patients may decline an offer. For example,
patients transplanted with a lung from donors over age 50 or with a history of smoking
generally have poorer post-transplant survival than patients who received lungs from
younger, healthier patients (Reyes and others, 2010). Although accepting low-quality
lungs may lead to poor post-transplant prognosis, declining offered lungs and remaining
on the waiting list is not without risk: the LAS system effectively allocates lungs to
patients most in need, but it does not guarantee that a patient who declines an organ
will be offered another if her condition deteriorates. The challenge is to weigh the
potential survival benefit to be gained by forgoing a low-quality organ in favor of waiting
for a high-quality organ against the risk that the patient may die before being offered a
high-quality organ.
One way to improve a patient’s anticipated survival time is to use available observa-
tional data to estimate the anticipated survival if the patient were to adopt a particular
strategy, or dynamic treatment regime (DTR), that dictates which organs should be
avoided. Formally, a treatment regime is a function that maps a patient’s treatment
and covariate history to an action to be taken (Moodie and others, 2007). Organ trans-
plantation is an example of a multi-stage treatment regime because each time the patient
is offered an organ, she must decide whether to accept it. For lung transplantation, one
potential treatment regime for a patient would be “for any viable lung transplantation
that is offered, decline the transplantation if the donor was ≥ 50 years old or had a
history of smoking ≥ 20 pack-years, otherwise accept the organ.”
Several statistical methods have been proposed to estimate the effect of comply-
ing with different DTRs on survival, both within the context of organ transplantation
and in other therapeutic areas. The parametric G-formula has been proposed to es-
timate the counterfactual distribution of various outcomes if patients were to follow a
particular DTR by developing a series of models for the waiting list and organ alloca-
tion process (e.g., patient arrivals to the waiting list, longitudinal changes in patient
6acuity and death while on the waiting list, organ arrivals and their quality, organ al-
location, and post-transplant survival. See Robins and Herna´n (2008) for a detailed
exposition of parametric G-formula). This is the approach used in the Thoracic Sim-
ulated Allocation Model used by UNOS to evaluate different allocation policies (see
the Thoracic Simulated Allocation Model (TSAM) User’s Guide, Scientific Registry of
Transplant Recipients, https://www.srtr.org/media/1201/tsam.pdf, accessed April 26,
2017). However, this approach requires developing and correctly specifying a multitude
of statistical models to obtain consistent estimators of the counterfactual survival.
Other approaches have sought to avoid modeling the entire waiting list and alloca-
tion process. Schaubel and others (2006) introduced a sequential stratification method
to test whether patients awaiting kidney transplantation should accept kidneys from
expanded criteria donors versus remaining on the waiting list and possibly receiving a
kidney from a traditional donor in the future. This method can be easily applied to
compare the effect of accepting versus declining other marginal organs. However, the
approach does not permit direct comparisons of different rules for declining an available
organ (e.g., declining all organs from donors over 50 years of age versus declining all
organs from donors over 40 years of age). Other methods include inverse probability
of compliance weighted (IPCW) Kaplan-Meier and Cox proportional hazards models
(Cain and Cole, 2009; Cain and others, 2010; Cole and Herna´n, 2008; Herna´n and oth-
ers, 2006; Herna´n and Robins, 2006; Orellana and others, 2010). In these methods a
patient’s follow-up time is considered only while she is “compliant” with a regime of
interest. When a patient becomes non-compliant with the regime, her follow-up time
is artificially censored. Observations are weighted according to the inverse of probabil-
ity of compliance to correct for the potential selection bias introduced by the artificial
censoring (Herna´n and others, 2006).
In organ transplantation, the anticipated survival for a given DTR depends on the
quality and availability of organs, and these depend on the strategies that other patients
follow to accept or decline an organ. This is conceptually similar, although not identi-
cal, to the “spillover” (Rubin, 1980) effect described in other contexts. An important
limitation in this context of the methods previously developed is that they estimate the
anticipated survival if a randomly selected patient were to follow a treatment regime,
and all other patients made no changes to their behavior. This may be of great interest
7to particular patients, but it may have less public health relevance. A policy dictating
that certain organs should be avoided would change the dynamics of the waiting list.
For example, because patients would decline organs, the size of the waiting list may
increase, thus reducing each patients probability of getting a transplant. A meaningful
analysis would therefore estimate the causal effect of a treatment strategy on survival
if the entire population of patients were to follow the strategy.
We demonstrate how we can estimate the causal effect of following a DTR, assuming
that all patients are following the DTR of interest, by re-weighting patients based on the
probability of following their transplant history in the counterfactual world in which all
patients follow the DTR of interest. In Section 2.2, we introduce a potential outcomes
framework in which to represent the effect of following a specific regime for accepting
or declining an offered organ, and we discuss treatment regimes that we can reasonably
estimate using available longitudinal data. In Section 2.3, we introduce a class of IPCW
estimators for the anticipated survival distribution if a random patient were to follow a
particular regime. The estimator can be used in both the case where no other patients
make changes to their behavior and in the case where all patients are following the
transplant regime. Section 2.4 discusses a metric of donor organ quality in the context
of the proposed estimators. In Section 2.5 we present the results of a simulation study
designed to test the small-sample properties of the estimators. Section 2.6 demonstrates
our method using data from UNOS, and we conclude in Section 2.7.
2.2 Statistical Framework
To aid the reader, we have included a summary of the notation used throughout the
manuscript in Appendix A. In general, uppercase letters represent random variables,
while lowercase letters represent realizations of those random variables.
2.2.1 Potential Outcomes
Consider a hypothetical population of patients eligible for organ transplantation. Let
T ∗(∞) denote the survival time from listing (i.e., entry on the waiting list) if the patient,
possibly contrary to fact, were to never receive a transplanted organ. Define T ∗(b, q) as
a random patient’s counterfactual survival time from listing if the patient were to receive
8an organ b days after listing with organ characteristics q ∈ Q, where Q is the set of all
donor characteristics. Define X∗(b) to be the covariates collected b days after listing for
a random patient including whether or not the patient had been previously transplanted
and had previously died prior to time b. Throughout, we use the overbar notation to
denote history, so that X
∗
(b) is the history of time-dependent covariates through b days
after listing. Assume that X∗(b) contains all the information that will be used to accept
or decline organs or order patients on the waiting list in any counterfactual scenarios
considered below. Because we do not observe T ∗(b, q) for all possible b and q, these are
known as potential outcomes. Let the set of potential outcomes for the ith patient be
Pi = {T ∗i (∞), T ∗i (b, q), X∗(b) ∀ b ≤ T ∗i (∞), q ∈ Q).
Inferring the distribution of T ∗(b, q) is not of primary interest, because there may
not be an organ offered to a particular patient b days after listing with characteristics q.
Formally, define a transplant regime for whether or not to accept an organ b days after
entering the waiting list as a function g which maps from X
∗
(b) and q to an indicator
for whether or not the patient should decline an offered organ. We further elaborate of
the regimes of interest in Section 2.2.3.
The quality and the availability of organs will vary depending on the rules other
patients use to accept or decline organs and the order in which cadaveric organs are
offered to potential recipients (i.e., the allocation rules). Therefore, when (or if) a
patient receives a transplant while following regime g is random and depends on the
regimes other patients use to accept or decline organs. We refer to this as “transplant
regime spillover.” With this in mind, define T ∗(g, g′) to be the time a randomly selected
patient would have lived if she followed regime g for declining offered organs and all
other patients follow regime g′. Note that, in principle, each patient could follow a
different regime, but for simplicity we only consider the scenario in which all other
patients follow a common regime g′. We make precise what we mean by “all other
patients follow regime g′” in Section 2.2.3. Finally, for the purposes of this paper, we
assume the allocation rules are the ones currently used and cannot be changed and,
therefore, do not index outcomes by the allocation rules used.
The goal of this analysis is to estimate Pr{T ∗(g, g′) ≥ t} for a given g, g′ ∈ G,
where G is the set of all possible treatment regimes. The distribution of T ∗(g, g′) is a
mixture distribution of well-defined counterfactual survival times. If we let B(g,g
′) and
9Q(g,g
′) be the random time from listing until organ transplantation and vector of organ
characteristics for a random subject if she followed regime g for declining offered organs
and all other patients follow regime g′, then fT ∗(g,g′)(t), the density of T ∗(g, g′), is equal
to ∑
x(t)
fT ∗(∞)|X∗(t) {t|x(t)}
[
t∏
s=1
1−
∑
q
ρ(g,g
′) {s, q|x(s)}
]
fX∗(t) {x(t)} (2.1)
+
t∑
b=1
∑
q
∑
x(b)
fT ∗(b,q)|X∗(b) {t|x(b)}
[
b−1∏
s=1
1−
∑
q
ρ(g,g
′) {s, q|x(s)}
]
× ρ(g,g′) {b, q|x(b)} fX∗(b) {x(b)} ,
where fT ∗(b,q)|X∗(b) is the conditional density of T
∗(b, q) given X∗(b), fX(t) is the den-
sity of time-dependent covariates, and ρ(g,g
′) {b, q|x(b)} is the probability of receiving a
transplant b days after listing with organ characteristics q given she is untransplanted
b − 1 days after listing with covariate history x(b) and the patient follows regime g
while all others follow regime g′. In the preceding, for simplicity of exposition, we have
assumed that the organ and patient characteristics are discrete but Equation (2.1) is
easily generalized to allow for continuous characteristics.
The derivation of the density of T ∗(g, g′) given in Equation (2.1) is similar to the
density of following a probabilistic dynamic treatment regime given in Murphy and
others (2001). However, the key difference is that the probability of initiating treatment
depends on the treatment regime other patients follow. “Spillover” typically refers to
situations in which the distribution of well-defined potential outcomes depends on the
treatment assignment of others, which is not the case here. However, we refer to this
as transplant regime spillover.
2.2.2 Observed Data
Assume that we observe a cohort of n patients listed for organ transplantation over a
period of p days. Let Ti be the observed time from entering the waiting list to death
for the ith patient, and Xij be the vector of covariates collected on the ith patient on
the jth study day, j = 1, . . . , p, including whether or not the subject was eligible (i.e.,
active on the waiting list) for transplantation. We assume that after transplantation
no additional covariate information is collected. For the purposes of this analysis we
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will assume that death information and transplant information are recorded daily as
they are in the UNOS registry and that the temporal ordering of events on a given
day is (1) time-dependent covariates are updated, (2) organs are assigned to patients
and are transplanted, and then (3) patients die. Define Nij = I(Li + Ti = j) and
Yij = I(Li + Ti ≥ j) to be the indicators for whether or not the ith patient died on the
jth day of the study and whether the ith patient was at risk for death on the jth day of
the study, respectively. In this study, all patients are followed until death or study day
p so that Nij and Yij are observed (i.e., not subject to right-censoring) for all patients
for j = 1, . . . , p.
Let Sj be the number of organs available for transplant on the jth day of the study,
let Qjk be the characteristics of the kth organ transplanted on the jth day, and let Aijk
be the indicator for whether or not the ith person received the kth organ on study day
j. Define the filtration
Eijk =
{
(Ailm, Qlm, Xil)l=1,...,j−1;m=1,...,Sl , Xij , Sj , (Aijm, Qjm)m=1,...,k−1 , Qjk,
}
.
That is, Eijk is the collection of all information on the ith subject at the time of the
kth transplant on the jth day but excluding whether the ith patient actually receives
the kth organ. Similarly define E·jk to be the collection of information on all subjects
i = 1, . . . , n prior to assigning the kth organ on the jth study day.
Given the data in the observational registry, one can determine the order in which
patients were offered the organ. Let Rijk be the rank of the ith patient on the waiting
list for the kth organ on the jth day of the study, and assume smaller Rijk indicates
higher rank, i.e., Rijk < Ri′jk implies that patient i will be offered the kth organ before
patient i′. Let Oijk =
∏
i′:Ri′jk<Rijk
1 − Ai′jk be the indicator that the ith subject is
offered the kth organ on the jth day.
2.2.3 Transplant Regimes
Because transplantation involves many logistical and clinical considerations (e.g. cross-
matching, physical examination of the organ anatomy), it is not practical to dictate
that a patient/physician must accept an offered organ. For the same reason we do not
attempt to infer the distribution of survival times under a regime that dictates when
a patient should receive an organ, for example, “receive a transplant the first day LAS
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> 50”, because an organ may not be available on that particular day. Instead we are
interested in transplant regimes that dictate whether or not an available organ should
be declined based on the organ quality and patient characteristics. We colloquially
refer to these organs as “low-quality” organs. Let Dijk (g,Eijk) be an indicator for
whether or not the kth organ on day j should be avoided by patient i under regime
g based on the organ and patient characteristics. To be precise, if the ith patient is
“following” or “compliant with” regime g, then the probability of accepting the organ
is pi
A(g)
ijk (Eijk) = pi
A(∅)
ijk (Eijk) {1−Dijk (g,Eijk)}, where piA(∅)ijk (Eijk) is the probability
of accepting the organ if no changes are made to her organ acceptance policy. We
will frequently refer to the transplant regime where patients make no changes to their
propensity to accept or decline organs, that is, they accept or decline organs with the
same probability that they accept or decline organs in the observed data. We refer to
this regime as ∅.
Similarly, let pi
O(g,g′)
ijk (E·jk) denote the conditional probability given the observed
data that the ith patient is offered the kth organ on day j given that she is following
regime g and all other patients are following regime g′. Note that piO(g,g
′)
ijk (E·jk) is the
probability that all patients who would have ranked higher than the ith decline the
organ in the counterfactual world in which they are all following regime g′. Finally, let
pi
(g,g′)
ijk (aijk, E·jk) to be the probability that ith person receives and does not receive if
aijk = 1 and aijk = 0, respectively, the kth available organ on the jth day given all
the observed information up until the time of assigning that organ, assuming the ith
patient is following regime g and all other patients are following regime g′. Note that
pi
(g,g′)
ijk (aijk, E·jk) =aijkpi
A(g)
ijk (Eijk)pi
O(g,g′)
ijk (E·jk) (2.2)
+ (1− aijk){1− piA(g)ijk (Eijk)piO(g,g
′)
ijk (E·jk)}.
Similarly, define pi
(g,g′)
ij (aij , E·jSj ) =
∏j
m=1
∏Sm
k=1 pi
(g,g′)
imk (aimk, E·mk), the probability that
the ith patient has her treatment history through study day j given that she is following
regime g and all other patients follow regime g′.
2.2.4 Identifying Assumptions
To estimate the causal effect of a treatment regime on the survival probability t days
after entering the waiting list, we must make the following assumptions to relate the
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observed data to the distribution of the potential outcomes (Robins and Herna´n, 2008).
We assume that 1−piA(g)ijk (E·jk) > 0 ∀i, j, k. That is, there is some non-zero probabil-
ity that a patient will remain compliant with a particular regime g of the form discussed
in Section 2.2.3. This is known as the positivity assumption.
We make the so-called sequential ignorability or no unmeasured confounders assump-
tion that the probability of receiving an organ at any time depends only on the observed
data up until that time and not additionally on any potential outcomes. This assump-
tion implies Aijk is conditionally independent of P given E·jk ∀ i = 1, ..., n, j = 1, ..., p,
and k = 1, . . . , Sj , where P = (P1, . . . ,Pn).
We assume that Ti = T
∗
i (t, q) if
∑Sj
k=1Ai,Li+t,k = 1 and
∑Sj
k=1Ai,Li+t,kQLi+t,k = q,
and similarly Ti = T
∗
i (∞) if
∑j
m=1
∑Sm
k=1Aimk = 0. This assumption is referred to as
the consistency assumption.
Finally, we assume that the availability and the characteristics of cadaveric organs
and when patients enter the waiting list does not depend on the characteristics of the
patients on the waiting list or the regimes that patients use to accept or decline organs.
We refer to this as the waiting list stability assumption.
2.3 Class of Estimators
To estimate Sr(g, g
′), the survival probability r days after entering the waiting list
for a random patient who follows regime g while all other patients follow regime g′,
we first estimate λt(g, g
′), the discrete-time hazard of death t days after entering the
waiting list, t = 1, . . . , r, for a randomly selected patient if she were to following regime
g and all other patients followed regime g′. Assuming for now that pi(∅,∅)ij (Aij , E·jSj )
and pi
(g,g′)
ij (Aij , E·jSj ) are known, we can estimate λt(g, g
′) by solving the estimating
equation
p∑
j=1
n∑
i=1
pi
(g,g′)
ij (Aij , E·jSj )
pi
(∅,∅)
ij (Aij , E·jSj )
{
Nij − Yijλt(g, g′)
}
I(j − Li = t) = 0. (2.3)
The vector of estimated discrete-time hazards λˆ(g, g′) =
{
λˆ1(g, g
′), . . . , λˆr(g, g′)
}T
is
the solution to the corresponding r-dimensional estimating equation. The survival
probability Sr(g, g
′) can easily be estimated as Sˆr(g, g′) =
∏
t≤r
{
1− λˆt(g, g′)
}
, which
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is equivalent to a weighted Kaplan-Meier survival estimator. Note that the IPCWs
pi
(g,g′)
ij (Aij ,E·jSj )
pi
(∅,∅)
ij (Aij ,E·jSj )
are a ratio of the probability of observing the transplant history under
regime g while all others follow regime g′ to the probability of the observed treatment
history for the ith patient.
Under the assumptions in Section 2.2.4, the left-hand side of equation (2.3) is a mean-
zero estimating function. For notational simplicity, define A·jk = {A1jk, . . . , Anjk} and
similarly for other random variables, A−ijk = {A1jk, . . . , Ai−1,jk, Ai+1,jk, Anjk}, and
Eij0 = {Ei,j−1,Sj−1 , Ai,j−1,Sj−1}. Let f denote the conditional mass function of Ti given
E·Li+t+1,0; g the conditional mass function of A−ijk given E·jk, Aijk; h the conditional
mass function of Qjk given E·j0, X·j , Sj ; u the conditional density of Sj given E·j0, X·j ;
v the conditional density of X·j given E·j0; and w denote the mass function of Li.
Finally, define hi and ui as above but conditioning on Eijk and Xij rather than E·jk
and X·j . Uppercase letters with overbars will be used to denote the corresponding
survival functions.
To show this that the estimating function has expectation zero, we begin by writing
the expectation of the estimating function for the ith patient as the sum of the estimating
function with respect to the observed data density.
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2.3.1 Estimating the Denominator of the Inverse Probability Weights
In most applications, the numerator and denominator of the weights are unknown and
must be estimated. We discussed in Section 2.2.3 that the probability a particular
patient is offered an organ depends on the probability that all others who rank higher
on the waiting list decline the organ. The denominator of the weights, however, is just
the probability of observed treatment history assuming all patients follow regime ∅ (the
regime in which all patients make no change in their propensity to accept or decline
organs). To estimate this probability, we only require a model for the probability that
patients accept organs given that they are offered based on the observed data. Although
many models are possible, a natural model for accepting an organ given that is organ
is offered is the logistic model
pi
A(∅)
ijk (Eijk;ϕ) =
{
1 + e−(ϕ0+ϕ
T
1 Xij+ϕ
T
2 XijQjk+ϕ
T
3 Qjk)
}−1
, (2.4)
where XijQjk is a vector of donor-patient interaction characteristics. These regression
parameters can be easily estimated by solving the estimating equation
n∑
i=1
p∑
j=1
Sj∑
k=1
Oijk
 Aijk − piA(∅)ijk (Eijk)
pi
A(∅)
ijk (Eijk)
{
1− piA(∅)ijk (Eijk)
}
 ∂piA(∅)ijk (Eijk)
∂(ϕ0, ϕT1 , ϕ
T
2 , ϕ
T
3 )
T
= 0. (2.5)
The estimated coefficient vector ϕˆ = (ϕˆ0, ϕˆ1
T , ϕˆ2
T , ϕˆ3
T )T can now be used to estimate
pi
A(g)
ijk (Eijk;ϕ) and pi
O(∅,∅)
ijk (E·jk;ϕ) =
∏
i:Ri′jk<Rijk
{(1−piA(∅)i′jk (Ei′jk;ϕ) in Equation (2.2)
to estimate the denominator of the weights in Equation (2.3), i.e., pi
(∅,∅)
ij
(
Aij , E·jSj
)
.
2.3.2 Estimating the Numerator of the Inverse Probability Weights
To estimate Sr(g, ∅), estimating the numerator of the weights is straightforward. In this
case,
pi
(g,∅)
ijk (aijk, Ejk) =aijkpi
A(g)
ijk (Eijk)pi
O(g,∅)
ijk (E·jk)
+ (1− aijk)
{
1− piA(g)ijk (Eijk)piO(g,∅)ijk (E·jk)
}
.
Although we wrote pi
O(g,∅)
ijk for consistent notation, note that if subject i is compliant
with regime g through study day j, then pi
O(g,∅)
ijk (E·jk) = pi
O(∅,∅)
ijk (E·jk) (the conditional
probability of being offered an organ depends on the actions of other patients, all of
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whom are following regime ∅) which can be is easily estimated as described above.
Similarly, pˆi
A(g)
ijk (Eijk) = pi
A(∅)
ijk (Eijk; ϕˆ) {1−Dijk (g,Eijk)}.
When g′ 6= ∅, estimating the numerator of the weights is more challenging. Although
estimating pi
A(g)
ijk using Model 2.4 is straightforward, if all patients are following regime
g′, we can no longer use
∏
i:Ri′jk<Rijk
{(1− piA(g′)i′jk (Ei′jk; ρˆ)}, to estimate the probability
of being offered an organ because the number of patients on the waiting list and their
characteristics at the time the organ is offered would be different than in the observed
data. That is, in the counterfactual world in which patients follow regime g′ the order
for offering an available organ would be different from the rank, Rijk, in the observed
data.
Note that pi
O(g,g′)
ijk (E·jk) = E{piO(g,g
′)
ijk (E
(g,g′)
·jk , E·jk)|E·jk} = E{piO(g,g
′)
ijk (E
(g,g′)
·jk )|E·jk},
where E
(g,g′)
·jk is the data we would have observed up to the allocation of the kth organ
on the jth day had all patients followed regime g′ and the ith patient followed regime g
and pi
O(g,g′)
ijk (E
(g,g′)
·jk ) is the probability the ith subject is offered the kth organ on the jth
day given the counterfactual data. Note that given E
(g,g′)
·jk calculation of the probability
of being offered an organ is straightforward and would follow a similar approach to that
outlined for the observed data.
However, analytically evaluating the outer expectation is challenging. Therefore, we
propose to estimate this quantity using Monte Carlo integration/summation. To do so,
we must be able to simulate E
(g,g′)
·jk given the observed data E·jk. We describe how one
can simulate such a hypothetical dataset with minimal assumptions.
Given E·jk, patient and organ arrival times and their characteristics are fixed.
To allocate organs, we assume that if in the observed data Oijk = 0 (i.e., we do
not know whether or not the ith subject would have accepted the kth organ on the
jth day) patients accept offered organs in the hypothetical dataset with probability{
1−Dijk(g,E(g,g
′)
ijk )
}
pi
A(∅)
ijk (E
(g,g′)
ijk ) for the ith subject and with probability{
1−Dijk(g′, E(g,g
′)
ijk )
}
pi
A(∅)
ijk (E
(g,g′)
ijk ) for all others. If in the observed data the patient
was offered the organ, then in the hypothetical dataset the patient accepts the organ
with probability 1 if Aijk = 1 and with probability 0 if Aijk = 0 (i.e., if in the observed
data we know a patient accepted or declined an organ than this is preserved in the
simulated dataset).
Similarly, because we condition on E·jk, patients in the simulated dataset begin with
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the same covariate trajectory as in the observed dataset. However, it is possible for a
subject in the observed dataset to remain on the waiting list in the simulated dataset
longer than in the observed one. In such a case, we need to simulate their covariate
trajectory until death or transplant. Rather than postulate a parametric model for
Xij given Xij′ , Aij′Sj′ = 0 (for j
′ < j), we use hot deck imputation. When discussing
the imputation, we avoid the “donor-recipient” verbiage common in the literature (for
example, see Andridge and Little (2010)), because that can obviously create confusion
here. We refer to an individual whose values are to be filled in as the “borrower” and
the pool of potential patients whose values could be used as the “lenders.”
If the ith patient was transplanted on the jth day in the observed data, the data for
the eligible lenders is the set[{
Xi′j′ , Xi′(j′+1), · · ·
}
,
{
(Ai′j′k)k=1,··· ,Sj′ , (Ai′(j′+1),k)k=1,··· ,S(j′+1) , · · ·
}
, Ti′
]
i′ 6=i
such that j−Li = j′−Li′ , that is, the potential data are the covariate history, transplan-
tation history, and death time for each lender, taken from the time where the lender had
been on the waiting list for as long as the borrower, but not necessarily concurrently.
The lender can be selected as the patient whose Xi′ minimizes |Xij − Xi′j′ | or some
other distance metric for multi-dimensional covariates (including past history of patient
covariates). The borrower’s information from time j is replaced by the lender’s data
beginning at time j′. If the lender received a transplant, the process may be repeated.
Typically, in Monte Carlo interegration one would simulate several datasets and
average the integrand across them to estimate pi
O(g,g′)
ijk (E·jk). However, in this applica-
tion, simulating such a dataset can be computationally intensive when combined with
resampling methods for standard error estimation, and we have found that simulating
a single dataset to estimate pi
O(g,g′)
ijk (E·jk) for all i, j, and k is sufficient. Note that to
estimate pi
O(g,g′)
ijk (E·jk) we do not need to simulate post-transplant outcomes.
Because estimating the numerator of the weights is a complicated function of the
observed data, we recommend estimating the standard error of Sˆr(g, g
′) using the non-
parametric bootstrap (Efron, 1979).
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2.4 Defining Lower Quality Organs
In some applications the definition of a “low-quality” organ may be defined a priori.
For example, we may define an organ as low-quality if the donors has smoked more
than 20 pack-years. Here, however, we consider treatment regimes of the type “decline
all organs in the lowest d percentile of donor quality.” In this scenario we define “low-
quality” as a continuous measure depending on donor and donor-recipient interaction
characteristics, and we estimate those combinations of characteristics that lead to poorer
survival. We can then estimate the anticipated survival if a patient were to avoid organs
below a certain threshold of the donor quality score. We assume that, given X
∗
(b), the
distribution of T ∗(b, q)− b (the potential residual lifetime after transplantation) follows
a discrete-time proportional hazards model. That is,
Pr {T ∗(b, q)− b = t} = λPTt exp
{
ξT1 X
∗
(b) + ξT2 Q+ ξ
T
3 X
∗
(b)Q
}
,
where λPTt is the baseline post-transplantation discrete-time hazard of death t days
after transplantation. We can estimate ξ =
(
ξT1 , ξ
T
2 , ξ
T
3
)T
using the observed data. For
an organ with characteristics q and a potential recipient with characteristics X
∗
(b), we
define the organ quality score as −
{
ξT2 Q+ ξ
T
3 X
∗
(b)Q
}
. We may now define a low-
quality organ as one that is below a threshold h, that is
Dijk(g,Eijk) = I
[
−
{
ξT2 Q+ ξ
T
3 X
∗
(j − Li)Q
}
< h
]
.
For example, because we assume that each organ is of different quality for each patient
due to patient-donor interaction characteristics, we can define the collection of potential
donor scores for the ith participant as
Qi =
([
−
{
ξT2 Qjk + ξ
T
3 X
∗
(j − Li)Qjk
}]
j=1,...,p,k=1,...,Sj
)
. The threshold hi for the ith
patient can be defined as a quantile of Qi.
2.5 Simulation Study
We designed a simulation study to test the small-sample performance of the pro-
posed estimators. The R code for the simulation is available at https://github.com/
jeffrey-boatman/transplant_simulation. Patient entered the waiting list and or-
gans arrived according to independent Poisson processes with rate parameters 0.5 and
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0.32, respectively. Participants were assigned a time-dependent covariate Xij repre-
senting disease severity, with higher scores indicating a greater hazard of death on the
waiting list and a greater need for transplantation. For each subject we generated
bi0 ∼ N(−1, 1) and bi1 ∼ N
(
1
365 ,
1
(4·365)2
)
. For study day j and a subject who arrived
to the waiting list on day Li, we let Xij = bi0 + bi1 · b j−Li30 c · 30, where b·c is the floor
function, so that covariate values were updated every 30 days. Patients and organs were
randomly assigned an ABO blood-type based on the probability observed in the analysis
in Section 2.6. Each organ was assigned a binary indicator variable for “low-quality”
with probability 0.5. For each organ arrival on study day j, the waiting list ranking was
based on patient-donor blood-type match (exact match and then compatible) and then
by the Xij value similar to the ordering for cadaveric lungs. Patients accepted the organ
with probability
{
1 + e(−ϕ0−x
T
ijϕ1)
}−1
with ϕ0 = −2.5 and ϕ1 = 0.25. In the results
reported here, we analyzed data collected over a 10 year observational period during
which the waiting list had reached a steady state. Specifically, we considered the first
10,000 days of each simulated dataset as a burn-in period (i.e., a period of time while
the waiting list stabilized analogous to the early years of cadaveric transplantation) and
used information collected over the following 10 years in the analysis.
We estimated the survival distribution assuming a randomly selected patient follows
the treatment regime g = decline all low-quality organs while (a) all other subjects
followed their current propensity to accept or decline an offered organ (followed regime
∅), or (b) all other subjects follow regime g. In addition to the IPCW estimators pro-
posed in Section 2.3 to estimate St(g, ∅) and St(g, g) we considered an ad hoc estimator,
Sˆt(NC), that censors individuals at the time of non-compliance from the regime g but
does not use any weights. This is not a consistent estimator for any causal effect of
interest; we include this ad hoc estimator as it is used commonly in practice. For each
estimator we report results for 1,000 Monte Carlo data sets. We estimated the standard
error of the estimators using 100 bootstrap re-sampled data sets.
St(g, ∅) and St(g, g), the true survival probabilities t days after entering the waiting
list for following regime g, are not available in closed form. Therefore, the survival curves
were estimated via Monte Carlo simulation. To estimate St(g, ∅), for each simulated
data set we randomly selected one observation and forced it to decline all low-quality or-
gans, whereas high-quality organs were accepted with probability
{
1 + e(−ϕ0−x
T
ijϕ1)
}−1
.
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Similarly, to estimate St(g, g), for each Monte Carlo dataset we forced all individuals to
decline all low-quality organs. The Monte Carlo data sets were independent of the ones
to evaluate the proposed estimators.
Table 2.1 shows the true survival probabilities, the bias of the estimators, and cov-
erage probabilities of 95% Wald-type confidence intervals for 4 time points. Although
Sˆt(NC) is a convenient and frequently used estimator, it does not consistently estimate
any causal effect of interest, and the bias is large for all time points for both causal
estimands. For all time points, St(g, ∅) is greater than St(g, g), indicating that in this
example, the causal estimand varies based on the question of interest. Importantly,
Sˆt(g, ∅) and Sˆt(g, g) are not interchangeable: the mean of each estimator is close to
its target, but Sˆt(g, ∅) is a substantially biased estimator for St(g, g), and Sˆt(g, g) is
a substantially biased estimator for St(g, ∅). The simulation results demonstrate the
good performance of the estimators, but, perhaps more importantly, they highlight the
danger of a naive analysis that fails to carefully specify the target of estimation: an
analyst attempting to estimate St(g, g) by using the more common estimator Sˆt(g, ∅)
may draw erroneous conclusions.
2.6 Application to UNOS Data
We illustrate our method with data from the UNOS national registry of lung trans-
plants and use the continuous measure of lung quality described in Section 2.4. The
observational period included transplants between May 4, 2005 and Sept 30, 2011.
We estimated ξ, the coefficients for the lung quality model, following the approach
in Section 2.4. To be eligible for inclusion in the analysis of the lung quality score,
patients must have been older than 18, not received a previous lung transplant, and not
listed for simultaneous heart transplant. A total of no = 9, 091 patients contributed to
the lung quality model. With these patients we modeled post-transplant survival with
recipient, donor, and recipient-donor interaction characteristics as predictors. These
included recipient age, donor age, LAS at time of transplant (LAS-T), an indicator for
donor history of diabetes, patient native disease group, transplant type, an indicator
for patient being on life support at time of transplant, donor race, donor-patient height
difference, and recipient body mass index. Restricted cubic spline basis functions with
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Table 2.1: Chapter 2 Simulation Results
Estimator Bias CP
Target t True Survival Sˆ(NC) Sˆ(g, ∅) Sˆ(g, g) Sˆ(g, ∅) Sˆ(g, g)
St(g, ∅) 180 0.785 0.010 -0.006 -0.018 0.954 0.735
360 0.636 0.029 -0.000 -0.036 0.966 0.519
540 0.533 0.039 0.003 -0.056 0.954 0.269
720 0.463 0.045 0.004 -0.073 0.951 0.152
St(g, g) 180 0.770 0.024 0.009 -0.003 0.882 0.967
360 0.599 0.066 0.037 0.001 0.333 0.978
540 0.471 0.101 0.065 0.006 0.045 0.972
720 0.382 0.125 0.084 0.007 0.014 0.960
Bias and Coverage Probabilities (CP) of 95% CIs from simulation. St(g, ∅) and
St(g, ∅) are the simulated true survival probabilities t days after entering the waiting
list for following regime g assuming either no other patients follow g or all other
patients follow g, respectively. Their estimators are Sˆt(g, ∅) and Sˆt(g, ∅). Sˆ(NC) is
a naive estimator that censors patients at non-compliance, but does not use weights.
4 knot points were used for continuous covariates to model nonlinear associations with
the log hazard. Estimated coefficients from the model are shown Appendix A.
To compare treatment regimes based on donor quality, inclusion criteria were the
same as above except that we now included both transplanted and non-transplanted
patients. The total number of patients was np = 13, 039. As predictors in the logis-
tic regression model for the probability of accepting we included patient age, current
LAS, time on the waiting list, native disease, patient-donor height difference, an in-
dicator for donor smoking ≥ 20 pack-years, and an indicator for donor age ≥ 50 and
its interaction with the patient age. As before, we used restricted cubic splines to
allow for a nonlinear associated with the log odds of accepting a donor organ. Esti-
mated coefficients from the model are shown in Appendix A. We created the simu-
lated data set used in estimating the numerator of the IPCWs as described in Section
2.3.2. For the ith patient transplanted on the jth day, the lender i′ was selected as
arg min
i′
(|LASij − LASi′j′ | : j − Li = j′ − Li′). If patient i′ later received a transplant,
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the process was repeated until the ith patient’s LAS trajectory was imputed through
time of death with no transplantation. Because LAS was the only time-varying covari-
ate considered in the organ acceptance model, no other variables aside from LAS were
imputed.
We considered treatment regimes of the form “decline all donor organs below the
qth percentile of donor quality scores if LAS is below M ; if LAS ≥ M , any donor
organ is acceptable”, where q and M can vary. LAS ranges from 0 to 100 (median
LAS-T 38.79; 25th and 75th percentiles: 34.23, 47.27) with greater score indicating
greater patient acuity and anticipated benefit for transplant. Examining these regimes
allows us to investigate the effect of avoiding low quality organs while the patient is
less acute. Importantly, we considered scenarios in which a single patient adopted the
treatment regimes as well as all patients on the waiting list to investigate the effect
of “transplant regime spillover.” Note that under regimes of the this form, patients
are never considered non-compliant for declining organs, they are only ever considered
non-compliant for accepting organs that violate the treatment regime. Because we
assumed that the organ would be of variable quality for each patient due to patient-
donor interaction characteristics, we estimated the organ quality for each potential
recipient for each possible donor in the dataset, and the distribution of these scores was
used to define the qth percentile for each patient.
We selected 4 scenarios to illustrate the proposed estimators. In each case we com-
pare the estimates to the estimated survival if no subjects were to alter their propensity
to accept an organ using the Kaplan-Meier estimator where all patients have a weight
of 1. The results are shown in Figure 2.1 and in Table 2.2, with standard errors esti-
mated using the bootstrap. In plot (a), we illustrate that the anticipated survival for
a random patient following the treatment regime “decline all organs when the LAS is
less than 40” is different depending on whether all patients follow the regime or only
the single individual does. In both cases, the anticipated survival is better than in the
observed data, but the benefit is increased if all patients follow the regime rather than if
only a single individual does. In particular, compared to the unweighted Kaplan-Meier
survival estimate, the 2-year cumulative percentage(SE) died is lower by 6.4(1.93) if all
patients follow the regime and by 2.0(1.31) for a single patient who follows the regime;
the 3-year cumulative percentage(SE) died is lower by 3.7(2.11) if all patients follow the
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regime and by 1.8(1.31) for a single patient who follows the regime. The benefit for a
single random patient who adopts the regime only comes from avoiding transplantation,
a procedure with significant peri-operative mortality while the patient is less acute. But
if all patients adopt the regime, this prevents relatively healthy patients (ones who are
unlikely to die soon on the waiting list) from receiving cadaveric organs and ensures
that more organs are available for the most acute patients.
Plot (b) shows the anticipated survival when all patients follow the regime with q
fixed at 100 (i.e., regimes in which patients declined all organs) and M varying from 35
to 50 in increments of 5. At lower values of M , there is an anticipated survival benefit.
That is, for patients with less acuity would benefit from delaying organ transplant until
their LAS increases, a finding consistent with previous research which found no antici-
pated survival benefit for those transplanted at low LAS (Vock and others, 2017, 2013).
However, as M increases above 40, the anticipated survival declines, and eventually the
risk of death exceeds the observed survival.
Plots (c) and (d) demonstrate that the effect of an organ quality threshold depends
on the LAS threshold M . Plot (c) shows that for M at 35, as q increases (i.e., declining
a greater number of organs) the survival continues to increase. That is, patients with
relatively low LAS are best served by avoiding all organ transplants, even with high-
quality organs. In plot (d) we consider the same scenario but with M = 50. Here there
is a modest survival benefit until q = 100, at which point the anticipated survival is
worse than in the observed data. Here it appears that patient with high LAS scores may
gain a modest survival benefit by declining the worst organs, but declining all organs
has a negative impact on survival. The small difference in expected survival among
different regimes with different organ quality thresholds is consistent with previous
work demonstrating the poor predictive ability of many donor factors on post-transplant
survival (Chaney and others, 2014; Reyes and others, 2010).
2.7 Chapter 2 Discussion
We have demonstrated how we can approach the problem of testing treatment regimes
when treatment is available stochastically and when the effect of the treatment regime
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Figure 2.1: Chapter 2 Application Results
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depends on whether other patients follow the proposed regime. Specifically, we in-
troduced a novel IPCW-based estimator developed to test the efficacy of a treatment
regime when either only a single individual uses a strategy versus the efficacy when the
entire population uses a strategy. Although we restricted our attention to the extreme
cases where either only one patient or all patients use a strategy, we could, in principle
estimate the causal effect for intermediate cases (e.g., 50% of the population adopts the
strategy) using simple modifications to the method.
The method relies heavily on correctly specifying the model for patients’ probability
of accepting organs. However, the method is attractive because many other processes
need not be modeled at all to obtain reasonable estimates of the anticipated survival
for following different regimes. In contrast to commonly used methods, we need not
specify models for the stochastic organ arrival process, patient additions to the waiting
list, the distribution of patient characteristics over time, survival on the waiting list in
the absence of transplantation, or for post-transplant survival, as is the case for the
thoracic simulated allocation model.
Although the method was developed in the context of treatment regimes for ac-
cepting organ transplants, an area in which data are publically available, the method
is relevant for many other to other applications. We could, for example, use the pro-
posed method to develop strategies on how to prioritize operating rooms in a hospital,
provided that we have access to an observational data set and can devise a means to
estimate the probability of observing treatment history in the observed data and in the
counterfactual world.
The results of the simulation and the application demonstrate the care an analyst
must use in specifying the target of estimation when attempting to estimate the efficacy
of a treatment regime when individuals are competing for treatment. In particular, we
demonstrated that substantively different conclusions on the effectiveness of a policy for
declining cadaveric organs can be reached depending on whether or not others on the
waiting list adopt the same policy. We did not make any attempt in this manuscript
to identify an optimal treatment regime that would be of the greatest benefit to an
individual, or a (possibly different) treatment regime that would be of the greatest
benefit to the population. We plan to address this issue in future work.
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Table 2.2: Chapter 2 Application Results
Which Organs LAS Who
Plot to Decline Threshold Follows 1 Year 2 Years 3 Years
(a) All 40 One -1.8%(0.43) -2.0%(0.91) -1.8%(1.31)
All 40 All -4.7%(1.63) -6.4%(1.93) -3.7%(2.11)
(b) All 35 All -3.6%(1.60) -4.7%(1.85) -1.4%(2.09)
All 40 All -4.7%(1.63) -6.4%(1.93) -3.7%(2.11)
All 45 All -1.7%(1.91) -1.2%(2.24) 0.6%(2.27)
All 50 All -2.7%(1.92) -1.3%(1.98) 1.4%(1.97)
(c) Worst 25% 35 One -0.3%(0.08) -0.5%(0.15) -0.7%(0.17)
Worst 50% 35 One -0.5%(0.09) -1.0%(0.15) -1.0%(0.27)
Worst 75% 35 One -0.8%(0.12) -1.3%(0.31) -1.2%(0.65)
All 35 One -1.0%(0.20) -2.1%(0.37) -1.7%(1.00)
(d) Worst 25% 50 One -0.8%(0.19) -0.9%(0.35) -1.3%(0.37)
Worst 50% 50 One -1.2%(0.44) -1.5%(0.63) -1.9%(0.64)
Worst 75% 50 One -0.5%(0.89) -0.5%(1.11) -0.7%(1.36)
All 50 One 2.0%(1.10) 3.2%(1.45) 3.3%(1.70)
Difference from Un-weighted Kaplan-Meier Survival(S.E.) in probability of death for
following the treatment regime. Negative numbers indicate a decreased cumulative
probability of death. All regimes have the form “Decline organs while LAS < LAS
threshold.” Estimates differ based on whether we assume one patient follows the
regime or all patients follow the regime. The columns indicate which organs should
be declined, the LAS threshold, and whether one or all patients are assumed to
follow the regime.
Chapter 3
Estimating Causal Effects from a
Randomized Controlled Trial
when Noncompliance is Measured
with Error
3.1 Chapter 3 Introduction
Twenty years ago, Benowitz and Henningfield (1994) argued the addictive properties of
cigarettes could be eliminated if the nicotine content were reduced to 0.4-0.5 milligrams
(mg) per gram of tobacco. In the United States, the Family Smoking Prevention and
Tobacco Control Act provides the Food and Drug Administration (FDA) with the regu-
latory authority to limit the nicotine content of cigarettes to lower levels (but not zero)
if such a regulation is likely to improve public health. As smoking remains the United
States’ leading cause of preventable death (U.S. Department of Health and Human Ser-
vices, 2014), nicotine reduction could have a substantial public health impact. However,
evidence for the effectiveness of such a policy is limited.
We recently reported the results of The Center for the Evaluation of Nicotine in
Cigarettes, project 1 (CENIC-p1), a 6-week randomized trial evaluating the effect of
nicotine reduction on tobacco use and dependence (Donny and others, 2015). Current
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smokers (n = 839) were randomized equally to one of seven groups consisting of a
usual brand control condition or experimental cigarettes with nicotine content ranging
from 15.8 mg per gram of tobacco (normal nicotine controls) to 0.4 mg per gram of
tobacco. In addition, the investigators included a group that received cigarettes with
0.4 mg of nicotine per gram of tobacco with high tar to understand the effect of tar
yield on cigarette use and dependence when nicotine content is reduced. Participants
were instructed to smoke only those cigarettes provided in the trial and were consid-
ered non-compliant if they smoked cigarettes not provided by the trial (i.e., non-study
commercial cigarettes). Although they were not given incentives to avoid smoking non-
study commercial cigarettes, they were encouraged to honestly report their smoking
behavior and were allowed to complete the trial regardless of compliance. During week
6 of the study, smokers randomized to the lowest nicotine condition had significantly
reduced tobacco use, dependence, and nicotine exposure compared to the usual brand
and normal nicotine control conditions.
The results of CENIC-p1 provide empirical support for nicotine reduction as a reg-
ulatory strategy, but they must be interpreted cautiously due to substantial noncom-
pliance to randomized treatment assignment. For example, among participants ran-
domized to smoke very low nicotine content (VLNC) cigarettes (cigarettes with 0.4 mg
of nicotine per gram of tobacco), 39% reported smoking at least 1 non-study cigarette
during week 6, and 80% reported smoking at least 1 non-study cigarette at some point
during the trial. A per protocol analysis, i.e., analyzing only compliant participants, is
problematic because compliance status is confounded, and compliers may differ system-
atically from non-compliers. The primary analysis of CENIC-p1 followed the intention-
to-treat (ITT) principle and analyzed the data from all participants according to their
randomized treatment assignment regardless of their compliance. An ITT analysis pro-
vides an unbiased estimator of the effect of a treatment or intervention when it is used
in an environment (e.g., target population, level of non-compliance, etc.) similar to the
clinical trial environment (Herna´n and Herna´ndez-Dı´az, 2012). However, if the nicotine
content of cigarettes were limited by regulation, and smokers no longer had legal access
to standard commercial cigarettes, the effect of nicotine reduction on smoking behavior
may be different than in the trial.
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Our goal is to estimate the effect of smoking VLNC cigarettes on cigarette con-
sumption and other measures of smoking behavior (dependence, withdrawal, etc.) in
the hypothetical world where a regulatory body has reduced the nicotine content of
cigarettes, and normal nicotine content commercial cigarettes are no longer available.
In the language of clinical trials, we wish to estimate the effect of smoking VLNC
cigarettes in the presence of complete compliance, i.e., the causal effect (Bellamy and
others, 2007). Methods for estimating the causal effect of an intervention in the pres-
ence of noncompliance are well-established and include inverse probability of compliance
weighted (IPCW) estimators (Cain and Cole, 2009; Herna´n and Robins, 2006), principal
stratification (Frangakis and Rubin, 2002), structural nested models estimated by G-
estimation (Robins, 1994), and instrumental variable approaches (Angrist and others,
1996).
Existing methods for estimating causal effects in the presence of noncompliance as-
sume that investigators know, without error, whether or not a participant was compliant.
In the context of randomized tobacco trials, like CENIC-p1, self-reported compliance is
subject to error and recall bias, and analyzing biomarkers of nicotine exposure has been
suggested as an alternate approach to identify non-compliant participants (Benowitz
and others, 2015). One recent study (Denlinger and others, 2016) evaluating biomark-
ers of nicotine exposure in participants exclusively smoking cigarettes with 0.4 mg per
gram of tobacco found that the 95th percentile for total nicotine equivalents (TNEs,
a biomarker of short-term nicotine exposure that measures most nicotine metabolites)
was 6.41 nmol/ml. Yet among the CENIC-p1 participants randomized to the 0.4 mg per
gram of tobacco arm, 63% of participants who self-reported full compliance during week
6 had TNE greater than 6.41 nmol/ml (Nardone and others, 2016). This demonstrates
that self-reported compliance can substantially misclassify whether or not participants
were compliant to their randomized treatment assignment. Although certain biomarkers
(e.g., TNE) may suggest that a participant’s self-reported compliance status is incor-
rect, no biomarker of nicotine exposure perfectly discriminates between compliers and
non-compliers.
We propose a novel estimator of the causal effect from a randomized clinical trial
when compliance status is measured with error. In contrast to existing methods, our
estimator explicitly accounts for the potential for misclassification of compliers and
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non-compliers. Although we treat compliance status as an unobserved variable, we
show how to weight participants by the product of their probability of compliance given
the observed data and the inverse probability of compliance given confounders, resulting
in a consistent and asymptotically normal estimator of the causal effect. Our simulation
results illustrate that in finite samples our estimator outperforms ad hoc causal methods
which ignore the error in compliance status by using either self-reported data or by using
an estimated indicator of compliance. When there is a perfect discriminator of compliers
and non-compliers, our estimator reduces to the standard IPCW estimator.
3.2 Causal Effect Estimators
3.2.1 Potential Outcomes and Target of Inference
We consider a hypothetical randomized clinical trial, where A = 1, 2, . . . , r denotes the
treatment group, which we assume is randomized. Let Z be a measure (without error) of
noncompliance with Z = 0 indicating full compliance and increasing Z indicating greater
noncompliance. For example, Z may be the number of non-study commercial cigarettes
smoked in week 6 of CENIC-p1 or the number of pills not taken in a therapeutic clinical
trial. Define the compliance indicator C = I(Z = 0), and note that Z and C are
not directly observed if noncompliance is measured with error. Define Y ∗(a, z) to be
the outcome of a randomly-selected participant if, possibly contrary to fact, we set
A = a and Z = z. Because for each participant we do not observe Y ∗(a, z) for all
a and z, Y ∗(a, z) is a potential outcome. For CENIC-p1, Y ∗(a, z) is the number of
study cigarettes with nicotine content a smoked per day in week 6 of the study if the
participant were to smoke z non-study cigarettes per day. The target of inference is
µ(a, 0) − µ(a′, 0) = E {Y ∗(a, 0)− Y ∗(a′, 0)}, the expected difference of the outcome
among randomized treatment groups a and a′ if all participants were to be compliant.
In the context of mediation literature, µ(a, 0)−µ(a′, 0) is known as the controlled direct
effect (Pearl, 2001), that is, the treatment effect when the mediator, number of non-
study cigarettes, is set at the fixed value of 0.
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3.2.2 Observed Data
Let Y be the observed outcome for a randomly-selected participant. Define the self-
reported compliance indicator variable D, with D = 1 indicating the participant reports
full compliance and D = 0 indicating that the participant reports any noncompliance.
Let X be a vector of patient variables, and let B be a biomarker indicating exposure
to the treatment A. In the context of CENIC-p1, Y is the number of study cigarettes
smoked per day during week 6 of the trial, B is a biomarker of nicotine exposure (e.g.,
TNE or cotinine) measured during week 6, D = 1 if the participant reports smoking 0
non-study cigarettes during week 6, and D = 0 if the participant reports smoking any
non-study cigarettes during week 6. Note that participants self-report D, and this may
be subject to error and recall biases.
3.2.3 Identifying Assumptions
To relate the distribution of the observed data to the distribution of the potential
outcome Y ∗(a, 0) in the case where C is observed, we make the following identifying
assumptions (Robins and Herna´n, 2008). First, we assume that we have measured
enough covariates such that the compliance status is conditionally ignorable. That is,
we assume the probability that a participant is compliant depends only on the ob-
served covariates X and A and not additionally on any potential outcomes; this implies
that E {C|A,X, Y ∗(a, 0)} = E(C|A,X) (no unmeasured confounders assumption). Al-
though there may be additional variables associated with C, e.g. the biomarker B, we
assume that there are no additional confounders aside from X. Second, we assume that
E(C|A,X) > 0 for all X and A, that is, there is positive probability of complying with
the randomized treatment assignment within all levels of the confounders (positivity
assumption). Finally, we assume that if Z = 0 and A = a, then Y = Y ∗(a, 0), that
is, if a participant is compliant with the trial protocol, then her observed outcome is
the same as it would be if the participant were forced to be compliant with the trial
protocol (consistency assumption). When C is unobserved, additional assumptions will
be necessary and will be stated where required.
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3.2.4 Proposed Estimators
We have stressed that C may not be directly observed due to measurement error or mis-
classification, but assume for now that E(C|A,B,X, Y,D) and E(C|A,X) are known.
We discuss in Section 3.3 how these expectations can be estimated even though C is
unobserved. We can estimate µ(a, 0) by solving the following estimating equation:
n∑
i=1
E (Ci|Ai, Bi, Xi, Yi, Di)
E (Ci|Ai, Xi) {Yi − µ(a, 0)} I(Ai = a) = 0. (3.1)
A similar estimator could be constructed for µ(a′, 0), and the difference in those esti-
mators could be used to estimate the treatment effect.
The estimating function with weights E(C|A,B,X,Y,D)E(C|A,X) is similar to a standard IPCW
estimator with weights CE(C|A,X) , but we have replaced the numerator with the con-
ditional expected value of compliance instead of an indicator variable for compliance
status. Note that if all participants self-reported compliance without error, or if there
exists a biomarker that can perfectly discriminate compliers from non-compliers, then
E (C|A,B,X, Y,D) equals 0 or 1, and the estimating function in Equation (3.1) simpli-
fies to the standard IPCW estimating function. Although it is not obvious that we can
obtain valid inference without observing C, we show in Section 3.4 that, under suitable
regularity conditions, µˆ(a, 0), the solution to the estimating equation, is a consistent and
asymptotically normal estimator of µ(a, 0). Because our estimator has an expectation,
rather than an indicator variable, in the numerator to account for potential misclassifi-
cation, we refer to the estimator as the Compliance Unsure RE-weighted estimator, or
CURE estimator.
3.3 Estimating the Weights
In practice, E(C|A,B,X, Y,D) and E(C|A,X) are usually unknown and must be es-
timated. To estimate these, we begin by re-writing E(C|A,B,X, Y,D) as a func-
tion of components that can be estimated directly from the observed data. We then
show how auxiliary data, if available, can be used to obtain a more precise estimate
of E(C|A,B,X, Y,D). Finally, we discuss how Eˆ(C|A,B,X, Y,D), the estimate of
E(C|A,B,X, Y,D), can be used to estimate E(C|A,X).
35
3.3.1 Estimating the Numerator of the Weights
First, using Bayes’ Theorem, we can write E(C|A = a,B = b,X = x, Y = y,D = d) as:
f(b|a, x, y, d, c = 1; ξ) · ρ(a, x, y, d;α)
f(b|a, x, y, d, c = 1; ξ) · ρ(a, x, y, d;α) + f(b|a, x, y, d, c = 0; ξ) · {1− ρ(a, x, y, d;α)} ,
(3.2)
where f is the conditional density of B given A,X, Y,D, and C indexed by parameter
vector ξ, and ρ(a, x, y, d;α) = Pr(C = 1|A = a,X = x, Y = y,D = d;α) indexed by
parameter vector α. Rewriting the expectation shifts the goal from estimating the con-
ditional expectation of C to estimating the conditional distribution of B|A,X, Y,D,C.
Note that B,A,X, Y and D are all observed random variables, which allows us to di-
rectly estimate the density of B|A,X, Y,D as the mixture density
g(b|a, x, y, d; ξ, α) =ρ(a, x, y, d;α) · f(b|a, x, y, d, c = 1; ξ)+
{1− ρ(a, x, y, d;α)} · f(b|a, x, y, d, c = 0; ξ). (3.3)
Thus, although we do not observe C, we can estimate E(C|A,B,X, Y,D) by estimating
the conditional density of B|A,X, Y,D. The maximum likelihood estimators of ξ and
α solve the score equations
n∑
i=1
∂
∂(ξT , αT )T
log g(Bi|Ai, Xi, Yi, Di; ξ, α) = 0. (3.4)
As is frequently the case with mixture distributions, Equation (3.4) may be difficult to
solve directly. In that case we can find the maximum likelihood estimates using the
EM algorithm (Dempster and others, 1977). In Appendix B, we give details of the EM
algorithm updates for ξ and α.
Equations (3.2) - (3.4) can sometimes be simplified based on the scientific problem.
For example, in some applications it may be reasonable to simplify the modeling as-
sumptions of the conditional density of B. In particular, according the directed acyclic
graph (DAG) in Appendix B, which is one plausible DAG for the CENIC-p1 data, B
may be conditionally independent of X given A, Y and C. We note that this assumption
is testable using observed data so the data analyst does not need to a priori assume the
correct causal structure. Additionally, it may be reasonable to assume that if D = 0,
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i.e., the participant reports noncompliance with the study protocol, then C = 0 with-
out error. That is, participants may not erroneously report noncompliance because in
most trials there is usually no incentive to be non-compliant. This would imply that
E(C|A,B,X, Y,D = 0) = 0.
3.3.2 Incorporating Compliance Information from an Auxiliary Study
Estimating mixture distributions is challenging in practice due to difficulties in iden-
tifying the underlying component densities. An advantage to estimating the mixture
distribution of B|A,X, Y,D for CENIC-p1 is the presence of an auxiliary study to eval-
uate biomarkers of nicotine exposure in fully compliant participants. Denlinger and
others (2016) present data on biomarkers of nicotine exposure for 23 smokers who vol-
unteered to be sequestered in a hotel for 4 nights with access to only cigarettes with
0.4 mg nicotine per gram of tobacco. These participants are known to be compliant,
and their data can be used in conjunction with the data from CENIC-p1 to estimate
the density of the biomarker in compliers. This will enhance our ability to identify
the underlying components of the mixture distribution for B|A,X, Y,D . While these
auxiliary data may seem unique to CENIC-p1, similar data arise in other settings. For
example, pharmacokinetic/pharmacodynamic data from early-phase clinical trials could
be used to help identify compliers in a phase III therapeutic clinical trial. In our appli-
cation we do not want to include these individuals’ outcomes, Y , in estimation of the
causal effect due to differences in smoking behavior between participants in the auxil-
iary and primary studies, but we do expect the distribution of B|A,X, Y,D = 1, C = 1
to be consistent across studies. This is known as the transportability assumption in the
measurement error literature (Carroll and others, 2006).
Let nk denote the number of participants in the auxiliary study, let m = n + nk,
and define the indicator variable K that equals 1 if the participant is included in the
auxiliary data or 0 if the participant is included in the main trial. We can incorporate
the auxiliary data when estimating ξ and α by solving the score equations
m∑
i=1
∂
∂(ξT , αT )T
{(1−Ki) · log g(Bi|Ai, Xi, Yi, Di; ξ, α)+
Ki · log f(Bi|Ai, Xi, Yi, d = 1, c = 1; ξ)} = 0. (3.5)
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3.3.3 Estimating the Denominator of the Weights
In most applications, the denominator of the weights will be unknown and must be esti-
mated. Because the denominator must be between 0 and 1, we specify a regression
model E(Ci|Ai, Xi) = pii(β) = g−1
{
β0 +X
T
i β1 + I(Ai = 2)β2 + · · ·+ I(Ai = r)βr
}
,
where g is a link function that maps from (0, 1) to R, such as the logit or probit
link, and β = (β0, β
T
1 , β2, . . . , βr)
T is a vector of unknown regression coefficients. If
E(C|A,B,X, Y,D) were known, we could estimate β by solving the estimating equa-
tion
m∑
i=1
(1−Ki){E(Ci|Ai, Bi, Xi, Yi, Di; ξ, α)− pii(β)}
pii(β) {1− pii(β)}
∂pii(β)
∂βT
= 0. (3.6)
That is, E(C|A,B,X, Y,D; ξ, α) is the “response” of the regression model. Note that
β can be estimated using standard software, for example, using the glm function in
R. Because E(C|A,B,X, Y,D; ξ, α) is between 0 and 1, this is analogous to mod-
eling proportions in a logistic or probit model. In the case that ξ and α are un-
known, we can stack Equations (3.5) and (3.6) and solve jointly, which is equivalent
to replacing E(C|A,B,X, Y,D; ξ, α) in Equation (3.6) with the estimated expectation
E(C|A,B,X,D, Y,D; ξˆ, αˆ).
3.4 Asymptotic Properties of the CURE Estimator
In discussing the asymptotic properties of the proposed estimator, for simplicity we
assume there are no auxiliary data of the type described in Section 3.3.2 and consider
only a single-arm trial with a = 1 for all participants, but the results easily generalize to
multi-arm trials. Under the assumptions in Section 3.2.3, the estimating function has
expectation equal to 0. The key to demonstrating this is to note that in expectation,
our proposed estimator is equivalent to an IPCW estimator in which the compliance
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status is known without error:
E
[
E (Ci|Bi, Xi, Yi, Di)
E (Ci|Xi) {Yi − µ(1, 0)}
]
= E
[
Ci
E (Ci|Xi) {Yi − µ(1, 0)}
]
= E
[
E {Ci|Xi, Y ∗i (1, 0)}
E (Ci|Xi) {Y
∗
i (1, 0)− µ(1, 0)}
]
= E
[
E(Ci|Xi)
E (Ci|Xi) {Y
∗
i (1, 0)− µ(1, 0)}
]
= 0. (3.7)
The 1st equality follows from iterated expectation. At this step, the argument of
the expectation is now equivalent to the case when C is known without error, and the
remaining equalities follow from assumptions stated in Section 3.2.3: the 2nd follows
from the consistency assumption and iterated expectation, and the 3rd follows from
the no unmeasured confounders assumption. Note that the result in Equation (3.7)
hold even if B is null. That is, we do not need to measure a biomarker of exposure
and could replace E(Ci|Bi, Xi, Yi, Di) with E(Ci|Xi, Yi, Di) and the estimating function
would still have expectation equal to zero. Nevertheless, conditioning on B allows us
to incorporate auxiliary compliance data as described in Section 3.3.2. Furthermore,
including a biomarker of compliance improves the discrimination between the compliers
and non-compliers which will improve the computational stability of the estimates in
the mixture distribution in Equation (3.3).
We can simultaneously estimate µ(1, 0), ξ, α, and β by stacking the estimating equa-
tions given in Equations (3.1), (3.5), and (3.6). Let Zi = (Ai, Bi, Xi, Yi, Di) be the
observed data on participant i and
∑n
i=1 ψi {Zi;µ(1, 0), ξ, α, β} denote the stacked es-
timating function. We showed above that the first component of ψi {Zi;µ(1, 0), ξ, α, β}
has expectation 0; the components corresponding to (ξT , αT )T and β have expectation
0 due to being score functions of a log likelihood and of a generalized linear model,
respectively. The fact that the stacked estimating function has expectation 0 implies
that, under suitable regularity conditions,
√
n
[{
µˆ(1, 0), ξˆT , αˆT , βˆT
}T − {µ(1, 0), ξT , αT , βT}T] D−→ N (0, U−1V (U−1)T ) ,
where V = E([ψi {Zi;µ(1, 0), ξ, α, β}] [ψi {Zi;µ(1, 0), ξ, α, β}]T ) and
U = −E
[
∂ψi{Zi;µ(1,0),ξ,α,β}
∂{µ(1,0),ξT ,αT ,βT }T
]
. The sandwich covariance matrix U−1V (U−1)T can be
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estimated using the empirical averages for U and V (see, for example, Stefanski and
Boos (2002)) or with the bootstrap (Efron, 1979).
Note that unlike IPW estimators when C is known where only the model for E(Ci|Xi)
must be correctly specified, the CURE estimator also relies on correctly specifying
the distribution of the mixture components in Equation (3.3) to obtain consistent and
asymptotically normal estimators.
We compare the relative efficiency of the CURE estimator to the standard IPCW
estimator when compliance is observed in order to understand the consequences of
measuring compliance with error. If E(C|X) and E(C|B,X, Y,D) are known and do
not need to be estimated, then the CURE estimator is more efficient than the standard
IPCW estimator with weights CE(C|X) . To see this, first note that
E
(
∂
∂ {µ(1, 0)}
[
Ci
E(Ci|Xi) {Yi − µ(1, 0)}
])
= E
(
∂
∂ {µ(1, 0)}
[
E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
])
,
so the difference in the limiting variance of the estimators is due to differences in the
variances of the estimating function. Next, we can write
var
[
Ci
E(Ci|Xi) {Yi − µ(1, 0)}
]
= var
[
Ci − E(Ci|Bi, Xi, Yi, Di) + E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
.
Then, because
cov
[
Ci − E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)} ,
E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
= E
([
E(Ci|Bi, Xi, Yi, Di)− E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
×
E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
)
= 0
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by iterated expectation, the variance of the estimating function with weights CE(C|X) is
var
[
Ci
E(Ci|Xi) {Yi − µ(1, 0)}
]
=var
[
E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
+
var
[
Ci − E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
≥var
[
E(Ci|Bi, Xi, Yi, Di)
E(Ci|Xi) {Yi − µ(1, 0)}
]
.
Thus, if all expectations are known and do not need to be estimated, the CURE estima-
tor is more efficient asymptotically than the standard IPCW estimator. To gain some
intuition for why this occurs, consider the case where compliance has no effect on the
outcome: the CURE estimator gains efficiency by simply taking a sample average of the
outcome among participants randomized to group a to estimate µ(a, 0), whereas the
IPCW estimator excludes participants who are non-compliant even though compliance
has no effect on the outcome. As the effect of compliance on the outcome strengthens,
E(C|B,X, Y,D) approaches an indicator function and the CURE estimator approaches
the standard IPCW estimator. In general, the CURE estimator borrows more data
from the non-compliers as the effect of compliance decreases, which increases efficiency
over the IPCW estimator.
A natural question is how estimating the weights impacts the variances of the es-
timators. Here we use notation consistent with the generalized linear model notation
introduced previously, and we remind the reader that E(C|X) can be written as pi(β).
When the weights are Cpi(β) , and β must be estimated jointly with µ(1, 0), the asymptotic
variance of µˆ(1, 0) is
E
[
{Y ∗i (1, 0)− µ(1, 0)}2
pii(β)
]
−H1H−12 HT1 ,
where H1 = E
[
Y ∗i (1,0)−µ(1,0)
pii(β)
∂pii(β)
∂β
]
and H2 = E
[
1
pii(β){1−pii(β)}
∂pii(β)
∂βT
∂pii(β)
∂β
]
. This inter-
esting result shows that the variance of µˆ(1, 0) with weights Cpi(β) is reduced when β is
estimated compared to when β is known (Lunceford and Davidian, 2004). When the
weights are E(C|B,X,Y,D;ξ,α)pi(β) , when ξ, α, and β must be estimated jointly with µ(1, 0),
and when their are no auxiliary data to use in estimating the parameters of the mixture
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density (3.3), then the large sample variance of µˆ(1, 0) is
E
[
E(Ci|Bi, Xi, Yi, Di)2
pii(β)2
{Yi − µ(1, 0)}2
]
+
2
[(−H3H−14 +H1H−12 H5H−14 ) (−H1H−12 )]
[
HT6
HT7
]
+
[(−H3H−14 +H1H−12 H5H−14 )T(−H1H−12 )T
]T [
H4 H8
HT8 H9
][(−H3H−14 +H1H−12 H5H−14 )T(−H1H−12 )T
]
(3.8)
where
H3 = −E
[
Yi − µ(1, 0)
pii(β)
∂E(Ci|Bi, Xi, Yi, Di)
∂(ξT , αT )
]
H4 = E
[
∂ log g(Bi|Xi, Yi, Di; ξ, α)
∂(ξT , αT )T
∂ · log g(Bi|Xi, Yi, Di; ξ, α)
∂(ξT , αT )
]
H5 = −E
[
pii(β) {1− pii(β)} ∂pii(β)
∂βT
∂E(Ci|Bi, Xi, Yi, Di)
∂(ξT , αT )
]
H6 = E
[
Ci {Y ∗i (1, 0)− µ(1, 0)}
pii(β)
∂ · log g(Bi|Xi, Yi, Di; ξ, α)
∂(ξT , αT )
]
H7 = E
[
E(Ci|Bi, Xi, Yi, Di) {Yi − µ(1, 0)} {E(Ci|Bi, Xi, Yi, Di)− pii(β)}
pii(β)2 {1− pii(β)}
∂pii(β)
∂β
]
H8 = E
[
E(Ci|Bi, Xi, Yi, Di)− pii(β)
pii(β) {1− pii(β)}
∂ log g(Bi|Xi, Yi, Di; ξ, α)
∂(ξT , αT )T
∂pii(β)
β
]
H9 = E
[
{E(Ci|Bi, Xi, Di, Yi)− pii(β)}2
[pii(β) {1− pii(β)}]2
∂pii(β)
∂βT
∂pii(β)
∂β
]
and H1 and H2 were defined previously. The last term in (3.8) is positive because it is
a quadratic form of a positive semi-definite matrix, but the middle term does not have
this property and is neither clearly positive nor clearly negative under all conditions.
Thus, although estimating the weights for the IPCW estimator is guaranteed to increase
the asymptotic efficiency of µˆ(1, 0), there is no such guarantee for the CURE estimator.
If C were observed and E(C|B,X, Y,D) were estimated using a regression model in
the CURE estimator, then we could make a definitive statement about the impact
of estimating (ξT , αT )T on the limiting variance of µ(1, 0), but this is not possible
when C is not observed and we used the approach described in Section 3.3. Also note
that the information matrix H4 will contain more information when auxiliary data are
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incorporated as described in Section 3.3.2, but this may be beneficial only for estimation
of the mixture density (3.3) in small samples, not for asymptotic efficiency of µˆ(1, 0).
3.5 Simulation Study
We designed a simulation study to test the finite-sample properties of the proposed
estimator. The R code for the simulation is available at
https://github.com/jeffrey-boatman/cure-estimator. For simplicity, we consider
a scenario in which all participants are assigned a single treatment, A = 1, and only
estimate µ(1, 0), rather than a difference in means between two treatment groups. To fa-
cilitate data generation, define C ′ as a latent continuous measure of compliance. We gen-
erated (C ′, X, Y ) from a multivariate normal distribution with mean vector (0, 10, 16)T
and covariance matrix Σ =

1.000 −0.573 −0.139
−0.573 2.000 1.715
−0.139 1.715 3.000
 . We define the compliance
indicator
C = I
{
C ′ > Φ−1(0.80)
}
, where Φ is the standard normal cumulative distribution
function. This gives Pr(C = 1) = 0.20, consistent with the preliminary estimates
of the compliance rate from CENIC-p1 (Nardone and others, 2016). We simulated
B ∼ N(−9.3− 0.8 ·C + 0.7 · Y, σ2) with 2 values of σ2, 0.818 and 0.663, to give an area
under the ROC curve of 0.8 or 0.9, respectively, for discriminating between compliers
and non-compliers. We let D = H1−C , where H is a Bernoulli random variable with
success probability 0.3 independent of other data, so that those truly compliant (C = 1)
always self-report compliance and for non-compliant participants (C = 0) H is an indi-
cator of whether or not non-compliance was reported with error. The data generated
are consistent with the DAG shown in the Appendix B, which is one possible DAG
for the CENIC-p1 data. Note that the DAG implies that B and X are conditionally
independent given C and Y (and A, which here has only one level).
We considered sample sizes of 225 (roughly the number of participants randomized
to the VLNC cigarettes in CENIC-p1), 500, and 1,000 and also included data from an
auxiliary study in which participants are known to be compliant as described in Section
3.3.2 equal to 10% of the size of the main clinical trial.
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We compared 5 estimators of µ(1, 0): (1) a per protocol estimator based on self-
reported compliance; (2) a self-reported inverse probability weighted (IPW) estimator
with weights equal to D
Eˆ(D|X) ; (3) an IPW estimator with weights equal to
C
Eˆ(C|X) ;
(4) a “cutoff” IPW estimator that first estimates E(C|B,X, Y,D) using the methods
described in Section 3.3.1, defines Cˆ = Eˆ(C|B,X, Y,D) > 0.5, and then uses the weights
Cˆ
Eˆ(Cˆ|X) ; and (5) the CURE estimator with weights
Eˆ(C|B,X,Y,D)
Eˆ(C|X) . Although we have
argued the IPW estimator cannot be used in CENIC-p1, we include it for comparison
to illustrate the cost of relying on imperfect measures of compliance. We assumed that
E(C|X,Y,D = 0) = 0, and observations with D = 0 did not contribute to estimation
of the mixture distribution. To estimate E(C|B,X, Y,D = 1) in the cutoff IPW and
CURE estimators, we assumed simple linear regression models with normal residuals
for B|Y,D = 1, C = 1 and B|Y,D = 1, C = 0; to estimate E(C|X,Y,D = 1) we
assumed a generalized linear model with probit link. To improve computation time,
we used a single set of starting values for the EM algorithm which were estimated
parameters from models fit using the actual compliance C. In applications when C
is unknown to the analyst and cannot be used to generate starting values, the EM
algorithm may require multiple iterations with different starting values to find the global
MLE, but the simulation nevertheless gave good results using only this one set of starting
values for each iteration. For the self-reported IPW, cutoff IPW, and CURE estimators,
the denominator of the weights was estimated using a generalized linear model with
probit link where the outcome is the numerator of the weights. We used the bootstrap
percentile method with 1,000 bootstrap re-sampled data sets to compute 95% confidence
intervals.
Table 3.1 shows the simulation results. Overall, the CURE estimator has very small
bias for both AUC of 0.8 and 0.9. With AUC of 0.8, the CURE estimator has higher
mean squared error than per protocol or IPW based on self-report, but with sample
size 1,000 the mean squared error is smaller; with AUC of 0.9, the CURE estimator
has lower mean squared error for sample sizes 500 and 1,000. The per protocol and
self-report IPW estimators show bias that is not attenuated with increasing sample size
and coverage probabilities which are not close to the nominal level. The cutoff IPW
estimator has low bias, but, surprisingly, for each sample size and AUC level, the CURE
estimator has much smaller mean squared error and coverage probability closer to the
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nominal 0.95 level. Unsurprisingly, the CURE estimator has higher mean squared error
than the IPW estimator, but the mean squared error of the CURE estimator approaches
that of the IPW estimator as the AUC increases. The simulation results demonstrate
that the CURE estimator has better small sample performance than per protocol and
self-report IPW when there is potential for misclassification. Furthermore, the CURE
estimator performs better than an ad hoc estimator that uses IPW with an estimated
indicator variable of compliance.
3.6 Application to the CENIC Data
We applied the CURE estimator to estimate the causal effect of VLNC cigarettes on the
number of cigarettes smoked per day using data from CENIC-p1. Although CENIC-p1
was a 6-week trial, for simplicity we are only concerned with compliance and outcomes
collected in the last week. In this analysis, we let A = 1 if the participant was random-
ized to smoke VLNC cigarettes (0.4 mg nicotine per gram of tobacco, high and low tar
groups combined) and let A = 2 if randomized to smoke usual brand cigarettes. All
other notation in this application is defined in Section 3.2.
The goal of this analysis is to estimate the causal contrast µ(2, 0) − µ(1, 0), the
expected reduction in cigarettes smoked per day during week 6 if smoking only VLNC
cigarettes versus smoking usual brand cigarettes. We estimate the causal effect by
estimating µ(2, 0) and µ(1, 0) separately and taking their difference. The usual brand
group is meant to represent smoking behavior with commercially available cigarettes
and, in that sense, participants in this group were never treated as non-compliant,
and µ(2, 0) was estimated using the sample average of the total number of cigarettes
smoked per day during week 6 (i..e. study plus non-study cigarettes). We consider the
4 estimators for µ(1, 0) discussed in the simulation study (excluding IPW because C is
unobserved) and include the ITT estimator for comparison.
As in the simulation, we assumed that E(C|A,X, Y,D = 0) = 0, and participants
with D = 0 did not contribute to estimation of the mixture distribution. Using the
biomarker log(TNE) measured at week 6 as the (only) biomarker B of exposure, we
estimated the probability of compliance for participants self-reporting compliance (i.e.,
45
D = 1) following the approach in Section 3.3.1. Specifically, in fitting the mixture dis-
tribution in Equation (3.3), we assume a simple linear regression model with normally
distributed errors for B|A = 1, Y,D = 1, C with no shared parameters between the
different levels of C. As in the simulation, we assume that B and X are conditionally
independent given A, Y and C, consistent with the DAG in Appendix B. We assumed
a logistic regression model for Pr(C = 1|A = 1, X, Y,D = 1), where the confounders
X included age, level of addiction (baseline cigarettes per day and log of TNE), mea-
sures of withdrawal (Minnesota Nicotine Withdrawal Scale at week 5 and maximum
acute withdrawal), and satisfaction with and craving for VLNC (Cigarette Evaluation
Scale and Questionnaire of Smoking Urges at week 5) and normal nicotine cigarettes
(Questionnaire of Smoking Urges at Week 5). We incorporated the data for the 23
participants from Denlinger and others (2016) who were known to be compliant to aid
in estimating the parameters of the mixture distribution as described in Section 3.3.2.
Multiple sets of starting values were tried for the EM algorithm, and we used those
values which gave the lowest negative log likelihood. We estimated the denominator
Pr(C = 1|A = 1, X) following the approach of Section 3.3.3 using a logit link with the
same predictors X described above. All confidence intervals were estimated using the
non-parametric bootstrap percentile method with 1,000 bootstrap resamples.
For the VLNC group, 137 of 222 (61.7%) participants self-reported compliance dur-
ing week 6. The left panel of Figure 3.1 shows a histogram of B = log(TNE) for
the self-reported compliers in the treatment group, the estimated mixture distribution,
and the complier and non-complier component distributions, which supports our para-
metric assumptions for the components of the mixture distribution. The right panel
shows the probability of compliance as a function of TNE and Y , the self-reported
number of cigarettes per day. We estimated Pr(C = 1|A = 1, D = 1) = 0.376, and
Pr(C = 1|A = 1) = 0.224, indicating a substantial proportion of self-reported com-
pliers were non-compliant. Estimated coefficients and parameters for the numerator
and denominator of the weights and 95% bootstrap confidence intervals can be found
in Appendix B. We also include a table giving some summary statistics of baseline
characteristics, confounders, and the biomarker week 6 log(TNE).
Table 3.2 shows the estimated causal effect of VLNC cigarettes on number of cigarettes
smoked per day. The Cutoff IPW gives the most optimistic estimate of the causal effect
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of the treatment, while the CURE estimate is more conservative. In contrast, the per
protocol and self-report IPW estimators give similar and more modest estimates of the
treatment effect. Although the CURE and Cutoff IPW estimates are similar, note that
the length of the 95% confidence interval is much wider for the Cutoff IPW estimator
than for the CURE estimator.
We typically expect the ITT estimator to be more conservative than estimators of
the causal effect. Although the ITT estimator was in fact more conservative than the
causal estimator, the difference is small considering the large proportion of noncom-
pliance. While this may seem counterintuitive, the impact of non-compliance may be
different compared to other clinical trials of medication. In the case of medication, we
expect a monotone dose-response relationship, and non-compliance with the medication
should dilute the treatment effect by reducing the dose received. Here, on the one hand,
non-compliant use of high nicotine cigarettes could actually reduce the need for study
cigarettes more than the study cigarette itself (e.g., by more effectively alleviating with-
drawal). Consequently, one might expect the number of study cigarettes smoked per
day to be lower in non-compliant participants than it would be if they were forced to be
compliant. On the other hand, non-compliance is also associated with individuals who
find VLNC cigarettes particularly unsatisfying. Such individuals might be less inclined
to continue to smoke or would smoke less if forced to be compliant.
The results presented here require us to assume that we have correctly modeled the
numerator and denominator of the weights and should be interpreted cautiously. Like all
models, the assumptions must be considered when interpreting outcomes, and conver-
gent analyses should be used to clarify the likely mechanism whenever possible. Finally,
it is important to note that in a regulatory environment in which VLNC cigarettes were
the only legally available cigarettes, we would expect that the proportion of smokers
using only VLNC cigarettes would be substantially higher than in CENIC-p1, but there
would still likely be some use of cigarettes with higher nicotine content (e.g., hoarding,
black market).
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3.7 Chapter 3 Discussion
Methods for estimating causal effects from randomized clinical trials when there is non-
compliance frequently rely on imperfect measures of compliance. Estimators that do
not acknowledge the error in the measures of compliance will result in biased estimators
of the causal effect. We developed a causal estimator that accounts for uncertainty in
compliance status by re-weighting a typical IPCW estimator by a participant’s proba-
bility of compliance given a biomarker of compliance, the outcome of interest, and con-
founders. Although we treated the true compliance status as unobserved, we showed
the probability of compliance can be estimated by assuming the distribution of the
biomarker follows a mixture distribution with separate components for compliers and
non-compliers. The simulation demonstrates that our proposed estimator has little bias,
good coverage probability, and smaller mean squared error than an ad hoc estimator.
The methods developed here have particular relevance to and were motivated by
regulatory tobacco research. There is usually substantial noncompliance in regulatory
tobacco trials due to the availability of commercial tobacco products. Furthermore,
the causal analysis using the methods we have developed, as compared to an ITT
analysis, is likely to better estimate the effect we would observe if regulations changing
the nicotine composition in cigarettes were enacted. However, our proposed method
also has broad applicability for clinical trials conducted in other therapeutic areas. The
method is particularly attractive in cases where investigators rely on imperfect measures
of compliance, such as participants’ self-report (e.g., pill counts, timeline follow back,
etc.) because the method explicitly accounts for the uncertainty of compliance status.
The preceding has assumed that either the outcome Y is not subject to measurement
or self-report error or that one is interested in the average causal effect on self-reported
outcomes. We show in Appendix B that if the observed outcome is subject to mea-
surement error, the proposed approach will estimate the causal effect if there were no
measurement error under mild assumptions.
Others have investigated the effect of and possible solutions to mediation estimators
when the mediator (e.g., compliance to randomized treatment group) is measured with
error (Ogburn and VanderWeele, 2012; Valeri and others, 2014). Most prior work has
examine the effect on regression-based estimators as opposed to our IPW framework.
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Additionally, our approach makes minimal assumptions about measurement error. In
particular, we do not need to assume that self-reported compliance (i.e., the covariate
measured with error) is a surrogate for true compliance for valid inference. That is, the
method does not require that D is conditionally independent of Y given C or that D is
conditionally independent of Y given C and X.
There are several limitations to our approach. First, estimating the parameters of the
mixture distributions may be computationally challenging, resulting in unstable param-
eter estimates. In our simulation, we relied on an auxiliary data set that included data
from participants whose compliance was known. However, such data sources are fre-
quently available in other settings as well, such as in pharmacokinetic/pharmacodynamic
studies. Second, we only considered compliance and outcomes during week 6 of the
CENIC-p1 trial. This was done mainly for simplicity, however, and we could develop a
longitudinal extension of the estimator, which is a likely subject of future work. Finally,
inverse probably weighted estimators are known to be inefficient. The efficiency of the
CURE estimator could likely be improved through an augmented weighted estimator
(Tsiatis, 2006).
Causal inference methods frequently rely on poor measures of compliance. Our
causal estimator weights participants by the product of their probability of compliance
given the biomarker of treatment exposure and the inverse probability of compliance
given confounders. Our approach suggests that, rather than improving methods of
eliciting compliance status from participants, perhaps a more fruitful of area of research
is in developing biomarkers of exposure. We restricted our attention to IPCW-like
weights and developed the method for a point exposure study, but future work may
develop causal estimators in other settings. Our hope is that the proposed methods
becomes a standard analysis by investigators estimating causal effects from clinical
trials.
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Table 3.1: Chapter 3 Simulation Results
n Estimator Bias MC SD Mean SE CP MSE
225 Per Protocol -0.629 0.173 0.174 0.045 0.426
Self-Report IPW -0.403 0.155 0.154 0.257 0.187
IPW -0.035 0.330 0.278 0.905 0.110
Cutoff IPWAUC=0.8 -0.140 0.860 0.740 0.978 0.758
CUREAUC=0.8 -0.119 0.768 0.689 0.976 0.603
Cutoff IPWAUC=0.9 -0.037 0.605 0.574 0.972 0.367
CUREAUC=0.9 -0.033 0.523 0.518 0.970 0.274
500 Per Protocol -0.636 0.114 0.117 0.000 0.417
Self-Report IPW -0.405 0.101 0.103 0.024 0.174
IPW -0.015 0.209 0.196 0.926 0.044
Cutoff IPWAUC=0.8 -0.010 0.665 0.659 0.983 0.442
CUREAUC=0.8 -0.047 0.530 0.571 0.978 0.283
Cutoff IPWAUC=0.9 0.021 0.368 0.419 0.982 0.136
CUREAUC=0.9 -0.021 0.277 0.344 0.965 0.077
1000 Per Protocol -0.633 0.086 0.082 0.000 0.408
Self-Report IPW -0.405 0.071 0.072 0.000 0.169
IPW -0.009 0.154 0.143 0.937 0.024
Cutoff IPWAUC=0.8 0.070 0.480 0.531 0.983 0.235
CUREAUC=0.8 -0.011 0.325 0.418 0.979 0.106
Cutoff IPWAUC=0.9 0.053 0.244 0.279 0.977 0.062
CUREAUC=0.9 -0.007 0.173 0.208 0.963 0.030
Simulation results; MC SD: Monte Carlo standard deviation of the estimator; Mean
SE: mean estimated standard error of the estimator; CP: coverage probability of
95% confidence interval; MSE: mean squared error. Subscripts indicate the area
under the ROC curve for discriminating compliers from non-compliers.
50
Estimated Biomarker Mixture Density and Component 
 Densities for Compliers and Non−Compliers
log(TNE)
D
en
si
ty
−2 0 2 4 6
0.
0
0.
1
0.
2
0.
3
0.
4
Mixture Density
Complier Component
Non−Complier Component
0 5 10 15 20
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Estimated Probability of Compliance as a Function 
 of TNE and Study Cigarettes per Day
TNE
Pr
(C
 = 
1)
10 Study CPD
15 Study CPD
20 Study CPD
Figure 3.1: Chapter 3 Application Results
Table 3.2: Chapter 3 Application Results
Estimator µˆ(2, 0) µˆ(1, 0) µˆ(2, 0)− µˆ(1, 0) SE 95% CI
ITT 22.18 15.37 6.81 1.57 (3.78, 10.07)
Causal Estimators
Per Protocol 22.18 15.12 7.07 1.80 (3.61, 10.63)
Self-Report IPW 22.18 15.19 6.99 1.67 (3.66, 10.38)
Cutoff IPW 22.18 14.83 7.35 3.03 (1.64, 12.99)
CURE 22.18 14.98 7.20 2.79 (2.01, 12.46)
Point estimates, standard error of the estimators, and 95% confidence interval of
the estimated causal effect for each estimator. µ(2, 0): mean cigarettes smoked per
day for the usual brand group. µ(1, 0): mean cigarettes smoked per day for the
VLNC group if all participants were to be compliant.
Chapter 4
Efficiency and Robustness of
Causal Effect Estimators When
Noncompliance is Measured with
Error
4.1 Chapter 4 Introduction
Randomized controlled trials (RCTs) are the gold standard for establishing causation
in research. Unfortunately, participant noncompliance to randomized treatment is a
common problem in human subject RCTs. This complicates assessing the causal effect
of an intervention because, although treatment assignment is randomized, the treatment
received is not randomized if subjects are noncompliant.
Intention to treat (ITT) estimators analyze data for all participants according to
randomized treatment group regardless of compliance to assigned treatment. Although
ITT provides an unbiased estimator of the effect of a treatment as it will be used in
practice (Herna´n and Herna´ndez-Dı´az, 2012), this may be different than the effect that
would be observed if all participants were to be compliant, that is, the causal effect of
the treatment (Bellamy and others, 2007). The causal effect is frequently of significant
interest as it may elucidate biological mechanisms or provide investigators and policy
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experts an estimated treatment effect if compliance can be increased or enforced.
Estimation of causal effects in the presence of noncompliance is often complicated
by the fact that compliance is confounded with other patient characteristics; that is,
patient characteristics X are associated with compliance C and with the outcome Y .
These characteristics, rather than the treatment effect, may be the cause of observed
differences between treatment groups among those observed to be fully compliant.
Several statistical methods have been proposed to estimate the causal effect of treat-
ment in RCTs when subjects may not be fully compliant. Instrumental variable ap-
proaches (Angrist and others, 1996) estimate causal effects by modeling the effect of
an “instrument” (i.e., a variable related to the treatment received but not related to
outcome after accounting for treatment received – treatment assignment in this case)
on compliance, and adjusting the ITT estimate by the strength of association between
the instrument and compliance. As the rate of noncompliance increases, the differ-
ence between the ITT estimate and the causal effect will tend to increase (Herna´n and
Robins, 2006). Another method, principal stratification (Frangakis and Rubin, 2002),
estimates causal effects by classifying participants according to joint potential values
of post-treatment variables and estimating causal effects within each stratum. For ex-
ample, in a randomized trial comparing two treatments, we could define one (latent)
stratum as participants who would comply if given either treatment A or B. Causal
effects are estimated within these latent strata by comparing potential outcomes under
the two treatments. This requires modeling assumptions because the potential outcomes
are generally known under only one treatment group and because the underlying strata
are unknown.
In contrast, inverse probability of compliance weighted (IPCW) estimators (Herna´n
and Robins, 2006) directly model the probability of compliance given the confounders.
Under the assumption of no unmeasured confounders (Robins and Herna´n, 2008), and
assuming that the model for compliance is correct, the weighted estimator is consistent
for the causal effect. Alternatively, if a regression relationship Y |X,C = 1 is known,
where C = 1 indicates compliance, this can be used to estimate the within-group coun-
terfactual mean by averaging fitted values of Y over the observed X for all participants
(Lunceford and Davidian, 2004). Augmented estimators combine IPCW and regression
estimators by “augmenting” the IPCW estimator with a regression component. When
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the regression model is correctly specified, augmented estimators are more efficient than
the IPCW estimators. Additionally, these estimators have the appealing property of
being doubly-robust: if either the regression model or the model for the probability of
compliance is correct, then the estimator is consistent for the causal effect even if the
other is misspecified (Tsiatis, 2006).
The methods described above share the common implicit assumption that compli-
ance is measured without error. As we argued in Chapter 3, this is often an unrealistic
assumption, particularly when compliance is based on participant self-report. Although
Chapter 3 was strongly motivated by an RCT evaluating very low nicotine content
cigarettes, investigators often rely on imperfect measures of compliance, such as the
number of pills remaining in a bottle returned to the pharmacy in a pharmaceutical
trial. Several papers have developed methods to estimate causal mediation effects when
the mediator may be measured with error or misclassified (in this context, compliance
is a mediator of the effect of assigned treatment and the causal effect of treatment is
equivalent to the controlled direct effect) (Ogburn and VanderWeele, 2012; Valeri and
others, 2014). However, these approaches typically make strong assumptions concern-
ing the measurement error/misclassification mechanism (e.g., surrogacy) which may not
reasonable in the context of all RCTs.
To address these limitations, we proposed in Chapter 3 an IPCW-like estimator
that, rather than weighting participants according to the inverse of the probability of
compliance given the confounders, weights participants according to the product of the
probability of compliance given the observed data, including biomarkers of exposure to
the treatment, and the inverse of probability of compliance given confounders. Although
we treated compliance C as an unobserved variable, we discussed how to estimate the
probability of compliance given the observed data by treating the distribution of the
biomarker of treatment exposure as a mixture distribution composed of compliers and
noncompliers. However, IPCW estimators are known to be highly variable due to insta-
bility caused by observations with large weights (Cole and Herna´n, 2008). Developing
regression-based and augmented IPCW estimators when compliance status is measured
with error represent potential approaches to reducing variability, but deriving these
estimators is not trivial.
In this work we develop a series of weighted estimators, regression-based estimators,
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and an augmented estimator for causal inference in RCTs when compliance is measured
with error under minimal assumptions on the measurement error process. Throughout,
we assume that we posses a biomarker of treatment exposure that can be used to identify
noncompliance. Such biomarkers are often available and can aid in estimation.
The remainder of Chapter 4 proceeds as follows. In Section 4.2, we describe the
potential outcomes framework, the observed data, and the assumptions necessary to
identify the causal effect. In Section 4.3, we develop weighted estimators, regression-
based estimators, and a doubly-robust augmented estimator to estimate causal effects in
RCTs when compliance is measured with error. In Section 4.4, we present a simulation
study to assess the finite-sample performance of the estimators. We apply the estimators
to data from the Center for the Evaluation of Nicotine in Cigarettes, Project 1(CENIC-
p1), an RCT of very low nicotine content (VLNC) cigarettes, in Section 4.5, and we
conclude in Section 4.6.
4.2 Preliminaries and Notation
4.2.1 Potential Outcomes and Target of Inference
We assume that data are collected from an RCT with treatment groups A = 1, 2, . . . , r.
Let Z indicate a measure of compliance without error, with Z = 0 indicating compliance
and Z 6= 0 indicating noncompliance. The precise definition of Z can be tailored to the
application. For example, in a pharmaceutical trial, Z may be the number of pills
not taken. Define the compliance indicator C = I(Z = 0), and note that we treat
both C and Z as unobserved data. Let Y ∗(a, z) be the outcome of a randomly-selected
participant if, possibly contrary to fact, A = a and Z = z. Because for each participant
we do not observe all values of Y ∗(a, z), Y ∗(a, z) is known as a potential outcome. The
target of inference is µ(a, 0) − µ(a′, 0) = E {Y ∗(a, 0)− Y ∗(a′, 0)}, the mean difference
in potential outcomes between treatment groups a and a′ if all participants were to be
compliant. In the context of mediation literature, µ(a, 0) − µ(a′, 0) is known as the
controlled direct effect (Pearl, 2001), that is, the treatment effect when the mediator,
the measure of compliance, is set at the fixed value of 0.
55
4.2.2 Observed Data
Let Y be the observed outcome for a random participant, let X be a vector of variables
associated with C and Y , and let B be a biomarker associated with exposure to treat-
ment A. For example, in pharmaceutical studies B might be the level of drug metabolite
in the blood or urine. In the data from the regulatory tobacco trial which motivates our
work, B is the level of nicotine in the urine. Let D indicate self-reported compliance,
i.e., D = 1 if a participant reports compliance, and D = 0 if a participant reports any
noncompliance. Note that we will introduce estimators that do not rely on D nor on
any surrogate of C. However, if self-reported compliance data are available, these data
can be incorporated into estimators depending on the scientific question of interest. For
example, it may be reasonable to assume that C = 0 without error if D = 0, that is, we
may assume that participants report noncompliance without error as there is usually
no social desirability associated with noncompliance. For the remainder of this paper,
we will assume that any self-reported measures of compliance are part of the vector X
for notational simplicity.
4.2.3 Identifying Assumptions
We make the following standard identifying assumptions (Robins and Herna´n, 2008)
to relate the observed data to the distribution of the potential outcomes. First, we
assume that we have collected sufficient covariates such that compliance is conditionally
ignorable. That is, we assume that C is conditionally independent of Y ∗(a, 0) given X
and A. This is known as the no unmeasured confounders assumption. Second, we
assume that for all levels X and A, there is positive probability of compliance, that is
E(C|A,X) > 0 for all A,X. This is known as the positivity assumption. Finally, we
assume that Y = Y ∗(a, 0) if A = a and Z = 0, that is, if a participant is assigned
treatment group a and is compliant, then her observed outcome is the same as it would
be if she were forced to be compliant. This is known as the consistency assumption.
These assumptions are required assuming either the traditional case where C is observed
or in the case we consider where C is unobserved. Further identifying assumptions are
required when C is unobserved, and these will be stated where required.
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4.3 Causal Estimators
For each causal estimator, we describe estimation of µ(a, 0), a mean for a single treat-
ment group. Similar estimators can be constructed for µ(a′, 0), and the estimated causal
contrast is taken as the difference in estimated means. We present traditional IPCW
estimators, regression-based estimators, and an augmented estimator for the case where
C is measured without error. For each of these cases, we develop the analogous esti-
mators for the case where C is measured with error, with the goal of making minimal
assumptions on measurement error. Rather than developing estimators that rely on a
variable measured with error, we take a different approach and treat C as an unobserved
variable.
4.3.1 Inverse Probability Weighted Estimators
In the case where C is observed, a traditional IPCW estimator for µ(a, 0) is the solution
to the estimating equation
n∑
i=1
I(Ai = a)Ci
E(Ci|Xi) {Yi − µ(a, 0)} = 0.
For the case where C is unobserved, we proposed in Chapter 3 estimating µ(a, 0) by
solving the estimating equation
n∑
i=1
I(Ai = a)E(Ci|Ai, Bi, Xi, Yi)
E(Ci|Ai, Xi) {Yi − µ(a, 0)} = 0. (4.1)
The estimating function with weights E(C|A,B,X,Y )E(C|A,X) is similar to the traditional IPCW
estimator with weights CE(C|A,X) , but the numerator of the weights is a conditional
expectation of C given the observed data rather than an indicator function.
Although C is unobserved, E(C|A,B,X, Y ) and E(C|A,X) can be estimated using
the observed data. Using Bayes’ theorem, we can write E(C|A = a,B = b,X = x, Y =
y), the numerator of the weights, as
f(b|a, x, y, c = 1; ξ) Pr(C = 1|A = a,X = x, Y = y)∑1
j=0 f(b|a, x, y, c = j; ξ) Pr(C = j|A = a,X = x, Y = y)
(4.2)
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where f is the conditional density of B given A,X, Y , and C indexed by parameter
vector ξ. The density of B|A,X, Y can be written as a two-component mixture density
g(b|a, x, y; ξ, α) =ρ(a, x, y;α) · f(b|a, x, y, c = 1; ξ)+
{1− ρ(a, x, y;α)} · f(b|a, x, y, c = 0; ξ), (4.3)
where ρ(a, x, y;α) = Pr(C = 1|A = a,X = x, Y = y;α) is indexed by parameter
vector α. The parameters for the mixture distribution, ξ and α, can be estimated via
maximum likelihood. Thus, although C is unobserved, we can estimate E(C|A,B,X, Y )
by substituting estimated parameters of the mixture distribution into (4.2). We refer to
the estimator for µ(a, 0) that uses components from the mixture density in (4.3) as the
CURE estimator. We showed in Chapter 3 that the CURE estimator is a consistent and
asymptotically normal estimator for µ(a, 0), provided that the models for the numerator
and denominator of the weights are correctly specified and that the assumptions in
Section 4.2.3 are met.
The maximum likelihood estimators of (ξT , αT )T are the solutions to the score equa-
tions
n∑
i=1
∂
∂(ξT , αT )T
log {g(Bi|Ai, Xi, Yi; ξ, α)} = 0. (4.4)
Equation (4.4) may be difficult to solve directly, in which case we can find the maximum
likelihood estimates of (ξT , αT )T using the EM algorithm (Dempster and others, 1977).
As an alternative to the factorization of E(C|A,B,X, Y ) in (4.2), we can instead
write E(C|A = a,B = b,X = x, Y = y) as
f(b|a, x, y, c = 1; ξ)h(y|a, x, c = 1; ζ) Pr(C = 1|A = a,X = x)∑1
j=0 f(b|a, x, y, c = j; ξ)h(y|a, x, c = j; ζ) Pr(C = j|A = a,X = x)
(4.5)
where h is the conditional density of Y given A,X, and C indexed by parameter vector
ζ. This allows us to estimate the joint conditional density of B, Y |A,X as the mixture
density
z(b, y|a, x; ξ, ζ, δ) =ω(a, x; δ)f(b|a, x, y, c = 1; ξ)h(y|a, x, c = 1; ζ)+
{1− ω(a, x; δ)} · f(b|a, x, y, c = 0; ξ)h(y|a, x, c = 0; ζ), (4.6)
where ω(a, x; δ) = Pr(C = 1|A = a,X = x; δ) is indexed by parameter vector δ. We
refer to the estimator for µ(a, 0) that uses components from the mixture density in
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(4.6) as the CURE+ estimator. Similar to the CURE estimator, the CURE+ estimator
is consistent assuming that the models for the density in (4.6) are correct and the
assumptions in Section 4.2.3 are met.
The maximum likelihood estimates of (ξT , ζT , δT )T are the solutions to the score
equations
n∑
i=1
∂
∂(ξT , ζT , δT )T
z(Bi, Yi|Ai, Xi; ξ, ζ, δ) = 0 (4.7)
As in Equation (4.4), Equation (4.7) may be difficult to solve directly, and the maximum
likelihood estimates of (ξT , ζT , δT )T can be found with the EM algorithm.
We note that unlike the CURE estimator, the CURE+ estimator requires specifying
the conditional distribution of Y given A, X, C. The advantage of having to specify
h(y|a, x, c; ζ) is that this may lead to greater separation between the compliers and
non-compliers, allowing for easier identification of the maximum likelihood estimates
using the EM algorithm. Additional advantages of this approach will become apparent
in Section 4.3.2.
In most applications, the denominator of the weights is unknown and must be es-
timated. Because the denominator is between 0 and 1, we specify a regression model
E(C|A,X) = pi(A,X;β) = g−1 {β0 +XTβ1 + I(A = 2)β2 + · · ·+ I(A = r)βr}, where
g is a link function that maps from (0, 1) to R, such as the logit or probit link, and
β = (β0, β
T
1 , β2, . . . , βr)
T is a vector of unknown regression coefficients. We can estimate
β by solving the score equations
n∑
i=1
E(Ci|Ai, Bi, Xi, Yi)− pii(Ai, Xi;β)
pii(Ai, Xi;β) {1− pii(Ai, Xi;β)}
∂pii(Ai, Xi;β)
∂βT
= 0 (4.8)
That is, E(C|A,B,X, Y ) is the “response” of the regression model for E(C|A,X).
Note that we can estimate β simultaneously with either (ξT , αT )T or (ξT , ζT , δT )T
by stacking Equation (4.8) with Equation (4.4) or (4.7), respectively. This is equiv-
alent to replacing E(C|A,X,B, Y ) in Equation (4.8) with the estimated expectation
E
(
C|A,B,X, Y ; ξˆn, αˆn
)
or E
(
C|A,B,X, Y ; ξˆn, ζˆn, δˆn
)
, where ξˆn, αˆn, ζˆn, and δˆn are
the estimates of ξ, α, ζ, and δ.
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4.3.2 Regression-Based Estimators
In the case where C is observed, as an alternative to IPCW estimation, we can instead
estimate µ(a, 0) by solving the estimating equation
n∑
i=1
{η(A = a,Xi; γ)− µ(a, 0)} = 0. (4.9)
where η(A,X; γ) = E(Y |A,X,C = 1) and γ is a vector of regression coefficients. This is
referred to as a regression-based estimator because, prior to solving Equation (4.9), the
conditional mean model for the outcome η(A,X; γ) must be specified. For example, we
can assume the mean model η(A,X; γ) = γ0 +X
Tγ1 + I(A = 2)γ2 + · · ·+ I(A = r)γr,
but other paramaterizations are possible. In the case where C is observed, one can
estimate the vector of regression coefficients γ by solving the estimating equation
n∑
i=1
Ci {Yi − η(Ai, Xi; γ)} ∂η(Ai, Xi; γ)
∂γT
= 0 (4.10)
To estimate µ(a, 0), Equations (4.9) and (4.10) can be solved jointly, which is equivalent
to replacing η (A = a,X; γ) in Equation (4.9) with η (A = a,X; γˆn).
Assuming that the model for E(Y |A,X,C = 1) is correct, regression-based esti-
mators are consistent estimators for µ(a, 0) and have smaller asymptotic variance than
IPCW estimators (Lunceford and Davidian, 2004). Note that regression-based esti-
mators have a potential advantage over IPCW estimators in that they do not require
specifying a model for E(C|A,X), and, unlike IPCW, they do not assign weights of 0
to some participants when estimating µ(a, 0), but this comes at the cost of needing to
correctly specify a model for E(Y |A,X,C = 1). See Lunceford and Davidian (2004) for
further discussion of advantages and disadvantages of weighted estimators compared to
regression-based estimators.
In the case where C is unobserved, both specifications of the mixture distribu-
tions in Equations (4.3) and (4.6) offer a means of using E(C|A,B,X, Y ) to estimate
E(Y |A,X,C = 1), which can then be used in Equation (4.9). Using E(C|A,B,X, Y ),
we can estimate the regression coefficients γ by solving the estimating equations
n∑
i=1
E(Ci|Ai, Bi, Xi, Yi) {Yi − η(Ai, Xi; γ)} ∂η(Ai, Xi; γ)
∂γT
= 0. (4.11)
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In expectation, weighting by E(C|A,B,X, Y ) is equivalent to the estimating function
in Equation (4.10). By iterated expectation,
n∑
i=1
E
[
E(Ci|Ai, Bi, Xi, Yi) {Yi − η(Ai, Xi; γ)} ∂η(Ai, Xi; γ)
∂γT
]
=
n∑
i=1
E
[
Ci {Yi − η(Ai, Xi; γ)} ∂η(Ai, Xi; γ)
∂γT
]
= 0.
Therefore, under suitable regularity conditions, we can obtain a consistent and asymp-
totically normal estimator for γ and µ(a, 0) provided that we can obtain a consistent
estimator of E(C|A,B,X, Y ).
As discussed in Section 4.3.1, E(C|A,B,X, Y ) can be estimated directly from mix-
ture components of the mixture density in (4.3). Thus we can consistently estimate
µ(a, 0) by jointly solving Equations (4.4), (4.9), and (4.11). Because this estimator
uses a weighted regression model, we refer to µˆ(a, 0), given by the solution to these
estimating equations, as the W-REG estimator. To be explicit, to obtain consistent es-
timation of µ(a, 0), W-REG requires correctly specifying each of the components of the
mixture distribution in (4.3) (i.e., Pr(C|A = a,X = x, Y = y;α) and the distribution
of B|A,X, Y,C) as well as the model for the conditional mean of Y |A,X,C = 1.
Note that, by estimating the parameters in Equation (4.6), we will already have
estimated the regression coefficients of the conditional mean model of Y |A,X,C = 1
(i.e., γ). Thus, we can simply estimate µ(a, 0) by jointly solving the estimating Equa-
tions (4.7) and (4.9), which is equivalent to replacing η (A = a,X; γ) in Equation (4.9)
with η (A = a,X; γˆn). Because this estimator uses a regression model with coeffi-
cients estimated from the mixture distribution using an EM algorithm, we refer to
this estimator as the EM-REG estimator. To be clear, EM-REG requires that the
analyst correctly specify all the components of the mixture distribution in (4.6) (i.e.,
Pr(C = 1|A = a,X = x;α) and the distributions of B|A,X, Y,C and Y |A,X,C).
W-REG has one potential advantage over EM-REG. The EM-REG estimator re-
quires that the analyst specify a model for E(Y |A,X,C = 1) prior to fitting the mixture
distribution, whereas W-REG first allows estimation of the biomarker mixture distribu-
tion without specifying a model for E(Y |A,X,C = 1). Because fitting mixture distri-
butions can be computationally demanding, fitting several models for E(Y |A,X,C = 1)
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as part of the mixture distribution and assessing model fit may be challenging. In con-
trast, once the weights E
(
C|A,X,B, Y ; ξˆn, αˆn
)
for W-REG have been estimated, the
analyst can easily fit multiple models and proceed using standard model checking and
diagnostics for E(Y |A,X,C = 1).
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4.3.4 Overview
In Table 4.1 we summarize the quantities that must be correctly specified and estimated
in order to achieve consistent and asymptotically normal estimators of µ(a, 0) for each
estimator. We also indicate which estimators will be consistent under misspecification
of h(Y |X,C) (the conditional distribution of Y given X and C) or E(Y |X,C). For
comparison, we also include the quantities that must be correctly specified to achieve
consistency in “traditional” IPCW, regression, and augmented IPCW estimators when
the compliance status is observed.
All estimators for µ(a, 0) will be consistent and asymptotically normal if the compo-
nents in Table 4.1 are correctly specified. Let Zi = (Ai, Bi, Xi, Yi) be the observed data
for the ith participant. Define ψi {Zi;µ(a, 0), λ} to be the mutli-dimensional estimat-
ing function from stacking the estimating functions for µ(a, 0) and any other nuisance
parameters that must be estimated. For example, for the CURE estimator, λ would
include λ = (ξT , αT , βT )T and ψ would include Equations (4.1), (4.4), and (4.8). Under
suitable regularity conditions,
√
n
[{
µˆ(a, 0), λˆT
}T − {µ(a, 0), λT}T] D−→ N (0, U−1V (U−1)T ) ,
where V = E([ψi {Zi;µ(a, 0), λ}] [ψi {Zi;µ(a, 0), λ, }]T ) and U = −E
[
∂ψi{Zi;µ(a,0),λ}
∂{µ(a,0),λT }T
]
.
The sandwich covariance matrix U−1V (U−1)T can be estimated using the empirical av-
erages for U and V (see, for example, Stefanski and Boos (2002)) or with the bootstrap.
4.4 Simulation
We conducted a simulation study to characterize the finite-sample performance of the
estimators described in Section 4.3. For simplicity, we considered a scenario with only
a single treatment group with A = 1 for all participants. We give special attention to
the cases where the conditional mean of Y given X,C = 1 is either specified correctly
or are misspecified.
To facilitate data generation, define the latent continuous measure of compliance C ′.
We generated (C ′, X1, X2) from a multivariate normal distribution with mean vector
67
(0, 2, 2)T and covariance matrix

1.000 0.200 0.075
0.200 1.000 0.200
0.075 0.200 1.000
. Using this covariance matrix,
X1 is more strongly associated with C
′ than is X2, and hence X1 is more strongly asso-
ciated with compliance. We defined the compliance indicator C = I
{
C ′ > Φ−1(0.8)
}
,
where Φ is the standard normal distribution function. This gives Pr(C = 1) = 0.20,
roughly the estimated probability of compliance in the application we consider in Section
4.5. We simulated the outcome as Y |X1, X2, C ∼ N
(
5− 2.25C +X1 +X2 + νX3, 1.252
)
,
where X3 = X1X2 for a model with an interaction and X3 = X
2
1 for a model with a
quadratic term, and where ν was equal to 0, 1, or 2. The biomarker B was generated
as B|Y,C ∼ N (−9.3− 0.8C + 0.7Y, 0.402). Our data generating mechanism implies
that B and X are conditionally independent given C, and Y . Although this assumption
is not required, it simplifies the simulation scenario, because in the correctly specified
conditional mean function of B in the mixture densities in (4.3) and (4.6), coefficients
for X1 and X2 are 0 and thus do not need to be estimated. As in Chapter 3, we included
participants comprising 10% of the sample who were known to be compliant, that is,
C = 1 without error. Data for known compliers was generated as described above, but,
rather than randomly generating C, we set C = 1 for these subjects. Known compliers
contributed to estimation of mixture distributions as follows. For known compliers, let
K = 1, and let K = 0 for all other subjects. Let nk denote the number of known com-
pliers, and let m = n + nk. To include known compliers in estimation of the mixture
distributions, we solved the modified score equations
m∑
i=1
∂
∂(ξT , αT )T
{(1−Ki) · log g(Bi|Xi, Yi; ξ, α)
Ki · log f(Bi|Xi, Yi, c = 1; ξ)} = 0
in place of the score equations (4.4), and
m∑
i=1
∂
∂(ξT , ζT , δT )T
{(1−Ki) · log z(Bi, Yi|Xi; ξ, ζ, δ)
Ki · log f(Bi|Xi, Yi, c = 1; ξ)} = 0
in place of the score equations (4.7). That is, known compliers contribute to estimation
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of the mixture distributions only through the information they contain about the con-
ditional density of B. They make no other contributions to estimation of µ(1, 0). We
considered sample sizes of 275, 550, and 1,100, including the known compliers. 1,000
Monte Carlo datasets were generated for each scenario.
We compared 8 estimators of µˆ(1, 0): the 5 estimators described in Section 4.3 and
three traditional estimators that assume C is known without error: 1) an IPW estimator
with weights equal to CE(C|X) , a regression-based estimator (REG) that estimates the
linear model Y |X,C = 1 and solves the estimating equation∑n
i=1 {E(Yi|Xi, C = 1)− µ(1, 0)}, and 3) an augmented IPW estimator (A-IPW) that
combines the IPW and REG estimators. Although C is treated as an unobserved
variable in our case, we included these 3 estimators to illustrate the consequences of
relying on imperfect measures of compliance.
For all models that require estimation of a mixture distribution to estimate
E(C|B,X, Y ), we assumed a linear regression model with normally distributed errors
for B|Y,C. For the CURE estimator, we estimated E(C|X,Y ) using a generalized lin-
ear model (GLM) with logit link. Note that for the CURE estimator, this GLM is not
exactly concordant with the data generating mechanism, but it is simple, easy to imple-
ment, and achieves reasonable small-sample performance. For the CURE+ estimator,
we assumed a linear regression model for Y |X,C with normally distributed errors, and
we estimated E(C|X) using a GLM with probit link. For the EM-REG estimator, we
used the estimated model for Y |X,C to solve the estimating equation given in Equation
(4.9). For the W-REG estimator, we used the estimated expectation E(C|B,X, Y ) to
solve Equation (4.11) and used the coefficient estimates to solve Equation (4.9). For
the A-CURE estimator, we obtained estimates of the necessary components using the
same approach as in the CURE and W-REG estimators.
In this simulation we considered the consequence of misspecifying the conditional
distribution of Y |X,C. Specifically, we considered the effect of omitting terms for X3
when ν 6= 0. Note that the CURE estimator is never misspecified in these scenarios
because the estimator does not require estimation of the conditional distribution of Y .
Because all models require a correctly specified model for B|Y,X,C, we only consider
scenarios where the model for B|Y,X,C is correctly specified.
For each model requiring estimation via the EM algorithm, we tried 4 sets of starting
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values, and we chose the model that gave the lowest negative log likelihood. The first
set of starting values used parameters and coefficients estimated from models using the
actual compliance C. The second set of starting values were the true values of the
parameters and coefficients; for misspecified models, these were found by estimating
parameters and coefficients from misspecified models using a very large sample. The
remaining sets of starting values were generated from the first set of starting values as
follows. For a coefficient or parameter D from the first set, the new starting value was
D +D × U , where U is a uniform random variable on the interval (-0.35, 0.35).
Scenarios in which the model for Y |X,C is misspecified occasionally resulted in
estimates of µ(1, 0) which were clearly outliers in the sampling distribution. In practice,
investigators are likely to fit a variety of causal models to seek converging lines of
evidence of the magnitude of a causal effect. Thus, outliers are generally easily identified
and omitted in practice, and we feel interpretation of simulation results may be more
meaningful with outliers removed. We present results with outliers excluded or included.
To remove outliers, for each estimator within each scenario, we defined upper and lower
limits as the median ±9/4× IQR (interquartile range; 9/4× IQR is roughly 3 standard
deviations for a normally distributed random variable). For results excluding outliers,
for each estimator the estimates falling below the lower limit or above the upper limit
were excluded.
Tables 4.2, 4.3, and 4.4 provide results when the regression model for the outcome
given confounders X and compliance C is correctly specified. All estimators show
a small amount of bias that is attenuated with increasing sample size. Among the
“gold standard” estimators which use the true compliance status, all were more efficient
than the proposed estimators that do not use the true compliance status. Across the
scenarios presented in tables 4.2, 4.3, and 4.4, the “gold standard” regression estimator
was substantially more efficient than the IPW estimator (the ratio of REG MSE to IPW
MSE ranged from 0.775 to 0.924). However, as expected, the augmented IPW estimator
recovers nearly all the difference in efficiency between IPW and REG.
Considering the estimators that do not use the true compliance status, CURE+ was
much more efficient than CURE when the true outcome model was correctly specified.
Using more data (i.e., the outcome) may more efficiently identify the components of
the mixture distribution leading to more efficient estimation of E(C|A,B,X, Y ). As
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is the case for “gold standard” estimators, regression-based estimators were generally
more efficient when the outcome model is correctly specified. EM-REG, which uses a
maximum likelihood estimator for the parameters of the outcome model, was generally
more efficient than W-REG. Augmenting the CURE estimator (i.e., A-CURE) improves
the efficiency with MSEs generally comparable to the W-REG estimator.
Tables 4.5 and 4.6 show the results when the coefficient for the interaction and
quadratic terms are non-zero but the model is misspecified, that is, the regression
model for the outcome omits the interaction or quadratic term. For the interaction
model, CURE performs well because there is no model misspecification for this estima-
tor. CURE+ shows bias that is only weakly attenuated with increasing sample size.
The EM-REG and W-REG estimators have small bias when the interaction coefficient
equals 1, but the magnitude of bias increases substantially for a stronger interaction.
For the quadratic models with misspecification, the bias of the CURE+, EM-REG, and
W-REG estimators is more substantial than for the interaction. The differences in the
performance of these estimators is explained by noting that the quadratic models include
a quadratic term for X1, and, because X1 is more strongly associated with compliance
than X2, the models with misspecification of E(Y |X,C = 1) tend to perform worse
under the quadratic model than under the interaction model. The A-CURE estimator
has bias commensurate with the CURE estimator, but the MSE of the A-CURE esti-
mator is now higher than the MSE of the CURE estimator. This is consistent with the
performance of the “gold standard” estimators in which the AIPW estimator was less
efficient than the IPW estimator when the outcome regression model was misspecified.
Tables 4.10 and 4.11 show the results when the interaction and quadratic models are
misspecified with outliers included.
Here we give some intuition for why the CURE+ and EM-REG estimators have a
large number of outliers and very large bias for some cases. We consider the Monte
Carlo iteration that gave the largest magnitude of bias for the CURE+ estimator for
n = 1, 100 under the misspecified quadratic model with coefficient ν = 2. Figure 4.4
shows the estimated values of E(C|B,X, Y ) (the numerator of the CURE+ weights) as
a function of X1. Several things are noteworthy by about this figure. First, the average
value of the estimated values of E(C|B,X, Y ) in the sample (i.e., an estimator of E(C))
is very close 0. Second, there is high separation of E(C|B,X, Y ) as a function of X1,
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so attempting to fit a probit model with these data results in very large magnitude
coefficients with some fitted probabilities close to 0 or equal to 0, so the weights can
become very unstable. Third, the marginal distribution of X1 is N(2, 1), so a value of
X1 ≈ 6 is clearly an outlier, and given the large quadratic coefficient, this individual will
have a very large value of Y . Under misspecified models, it appears that the model fitting
in the EM algorithm favors labeling a single outlying individual as compliant and all
others as non-compliant. Given that this is the only individual with E(C|B,X, Y ) ≈ 1,
this individual’s outcome has a large impact on the estimator. Informal examination
of other iterations with a high values of error had similar problems. The EM-REG
estimator will have similar problems as the estimated model for E(Y |X,C = 1) is
essentially based on a single individual.
In Appendix C.1, we show analogous results for simulations that do not include par-
ticipants who are known to be compliant. In general, the performance of the estimators
is similar to the case where known compliers are included.
4.5 Application to CENIC-p1 Data
We applied the 5 estimators described in Section 4.3 to data from CENIC-p1 to estimate
the causal effect of VLNC cigarettes on the number of cigarettes smoked per day during
week 6 of the trial. CENIC-p1 included seven treatment groups: a usual brand control
condition and six experimental conditions with nicotine content ranging from 15.8 mg/g
of tobacco to 0.4 mg/g of tobacco. In addition, one condition had 0.4 mg/g of tobacco
and high tar to evaluate the impact of tar yield on the effect of nicotine reduction.
For the purposes of this illustration, we focus on the contrast between the two VLNC
conditions (i.e. 0.4 mg/g and the 0.4 mg/g, high tar conditions, combined) versus the
usual brand control condition. As in Chapter 3, we only considered compliance and
outcomes during week 6 of the trial. We let A = 1 if the participant was assigned to
smoke VLNC cigarettes (n = 242), and A = 2 if the participant was assigned to smoke
usual brand cigarettes (n = 118). In this study, subjects are considered noncompliant
if they smoke cigarettes which are not provided as part of the study (i.e., commercial
or “non-study” cigarettes).
The goal of the analysis was to estimate µ(2, 0)− µ(1, 0), the expected reduction in
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Figure 4.1: Estimated E(C|B,X, Y ) as a function of X1 for the CURE+ estimator with
the largest error for n = 1, 100, misspecified model with quadratic coefficient of 2
cigarettes smoked per day during week 6 if smoking only VLNC cigarettes. Because the
usual brand group is meant to represent smoking of commercial cigarettes, all partici-
pants in this group were treated as compliant even if they reported smoking non-study
cigarettes (i.e., cigarettes that were not provided by trial personnel). Thus, µ(2, 0) is
the sample average of the number of cigarettes smoked per day for this group.
For the CURE and CURE+ estimators, we estimated the probability of compliance
following the approach in Section 4.3.1 using the (natural) logarithm of total nicotine
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equivalent (TNE) measured at week 6 as the biomarker B. In fitting the mixture distri-
butions in Equations (4.3) and (4.6), we assumed a linear regression models for B|Y,C
with normally distributed errors and no shared parameters between different levels of
C. As in the simulation, we assumed that B and X are conditionally independent given
C and Y . As described in (Denlinger and others, 2016), CENIC-p1 also included an
auxiliary study that included data from 23 smokers who volunteered to be sequestered
in a hotel for 4 nights with access to only VLNC cigarettes. These participants are
known to be compliant, and we incorporated B and Y from these individuals to as-
sist in estimation of the mixture densities. Chapter 3 describes in detail how data for
these participants can be incorporated. Briefly, these individuals contribute data to
the likelihood for the distribution of B|Y,C = 1, but they make no other contribu-
tions to estimation (i.e., their outcomes are not used to estimate the causal effect, and
their covariates X are not used in any way). We assumed logistic regression models for
Pr(C = 1|X,Y ) and Pr(C = 1|X) of Equations (4.3) and (4.6), where the confounders
X included age, level of addiction (baseline cigarettes per day and log of TNE), mea-
sures of withdrawal (Minnesota Nicotine Withdrawal Scale at week 5 and maximum
acute withdrawal), and satisfaction with and craving for VLNC (Cigarette Evaluation
Scale and Questionnaire of Smoking Urges at week 5) and normal nicotine cigarettes
(Questionnaire of Smoking Urges at Week 5). For the distribution of Y |X,C, we as-
sumed linear regression models with linear terms for all X, with normally distributed
errors and no shared parameters between different levels of C. As in Chapter 3, we
assumed that individuals with A = 1 who self-reported any noncompliance (that is,
D = 0 using Chapter 3 notation) reported noncompliance without error, and we let
Pr(C = 1|X,Y ) = 0 for these individuals. As a result, these individuals did not con-
tribute to estimation of the mixture distribution. For both the CURE and CURE+
estimators, we assumed a logistic model for E(C|X) using X as described above. For
the EM-REG estimator, we used the estimated model for Y |X,C to solve the estimating
equation given in Equation (4.9). For the W-REG estimator, we used the estimated
expectation E(C|B,X, Y ) to solve Equation (4.11) and used the coefficient estimates to
solve Equation (4.9). For the A-CURE estimator, we combined the CURE and W-REG
estimators. We used the bootstrap percentile method with 1,000 bootstrap re-sampled
data sets to compute 95% confidence intervals. In Section C.2 of Appendix C we show
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point estimates and 95% CIs for all all components required to implement the various
causal estimators.
Table 4.12 shows the estimated causal effect of VLNC cigarettes on number of
cigarettes smoked per day. The CURE estimator gives the most optimistic estimate
of the causal effect. The W-REG and A-CURE estimators give similar estimates and
are close to the ITT estimate. The CURE+ estimator and EM-REG estimators give
similar and more conservative estimates. As expected from the simulation, the A-
CURE estimator and the regression-based estimators have smaller estimated standard
error (SE) than the CURE estimator. Although reductions in SEs may be possible by
including interaction and higher-order terms, the limited sample size in this application
restricts our ability to explore more complex models for Y. Consequently, we do not
recommend the CURE+ and EM-REG estimators in practice unless a large sample size
is available. Although the W-REG estimator has smaller SE than the CURE+ and
EM-REG estimators, for the same reason we do not recommend this estimator for small
samples. Finally, we note that the estimators presented here require us to assume that
we have correctly modeled a variety of conditional densities described in Table 4.1 and
should be interpreted cautiously. As for all models, the assumptions must be considered
in the interpretation, and converging lines of evidence should be sought to clarify causal
mechanisms.
4.6 Chapter 4 Discussion
Although a variety of well-established methods are available to estimate causal effects
from RCTs, these methods assume that compliance is measured without error. This is
an unreasonable assumption in many cases, particularly when compliance is measured
by participants’ self-report. We explored a variety of weighted estimators, regression-
based estimators, and an augmented estimator for use when compliance is measured
with error.
All the proposed models performed well when the models were correctly specified. In
particular, the regression-based estimators (EM-REG and W-REG) perform well, likely
because they are able to average over all participants rather than giving very small
weights to some participant. However, the regression-based estimators and the CURE+
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estimator do not perform well under misspecification, and they rely on correctly spec-
ifying the distribution or mean model for the Y |A,X,C = 1 for consistency. For these
reasons, we do not recommend them in practice unless investigators have confidence
that the model can be at least approximately correctly specified.
Although we did not explore misspecification of the models for the CURE estimator,
the CURE estimator has intuitive appeal because it relies primarily on the mixture dis-
tribution of the biomarker to discriminate compliers and non-compliers. As we demon-
strated via simulation, the A-CURE estimator can be more efficient than the CURE
estimator by augmenting with a regression function. The A-CURE estimator has the
appealing property of being doubly-robust, but we note that the double robustness only
follows by first assuming that the mixture distribution in Equation (4.3) is correctly
specified.
The current work has some important limitations. As for all causal methods, the
estimators require strong and untestable assumptions, and the causal effects estimated in
the application must be interpreted with this in mind. In the application we considered
outcomes and compliance during week 6 only. A more thorough analysis may develop
a longitudinal extension of these estimators. This is a likely subject of future work.
We developed and evaluated the performance of novel estimators of causal effects
when compliance is measured with error. The simulation and application results suggest
that the CURE and A-CURE estimators are good choices for investigators, but efficiency
gains can be made by using the regression-based estimators if investigators are willing to
assume that regression model Y |A,X,C = 1 can be specified approximately correctly.
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Table 4.12: Chapter 4 Application Results
Estimator µˆ(2, 0) µˆ(1, 0) µˆ(2, 0)− µˆ(1, 0) SE 95% CI
ITT 22.18 15.37 6.81 1.57 (3.78, 10.07)
Causal Estimators
CURE 22.18 14.98 7.20 2.87 (1.46, 11.63)
CURE+ 22.18 16.98 5.20 3.11 (0.36, 11.97)
EM-REG 22.18 16.80 5.38 2.73 (1.56, 12.54)
W-REG 22.18 15.53 6.65 2.48 (1.85, 11.58)
A-CURE 22.18 15.47 6.71 2.55 (1.75, 11.48)
Point estimates, standard error of the estimators, and 95% confidence interval of
the estimated causal effect for each estimator. µ(2, 0): mean cigarettes smoked per
day for the usual brand group. µ(1, 0): mean cigarettes smoked per day for the
VLNC group if all participants were to be compliant.
Chapter 5
Conclusion
Causal inference is often one of the primary goals of public health research, but establish-
ing and estimating causal effects can be complicated due to confounding in observational
data or in RCTs with noncompliance. We considered two non-standard situations and
proposed novel causal estimators for these scenarios.
In Chapter 2, we developed estimators for the causal effect of solid organ transplan-
tation treatment regimes. Standard IPCW estimators have an important limitation in
this context: they estimate the anticipated survival for a random patient who adopts
a treatment regime. This may have relevance for individual patients, but it may have
limited usefulness for public health researchers. A more meaningful analysis would esti-
mate the anticipated survival for a random patient assuming that the entire population
of patients on the transplantation waiting list adopt the strategy. We developed a class
of estimators that can estimate causal effects for either scenario, so that the analysis
can be tailored to appropriately address the question of interest. We developed the
estimators to estimate the anticipated survival for pre-specified treatment regimes but
did not attempt to identify an optimal treatment regime that maximizes the anticipated
survival probability. The method could potentially be modified to identify an optimal
treatment regime using, for example, functional regression, where the survival curve is
the outcome, and parameters defining the regime are predictors.
In Chapters 3 and 4, we considered estimators of causal effects from RCTs with im-
perfect measures of compliance. The proposed estimators were strongly motivated by a
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regulatory tobacco RCT, but we argued that compliance is frequently measured with er-
ror in other settings as well. Rather than relying on an imperfect measure of compliance,
we treated compliance as an unobserved variable and showed how to construct weights
by using the available data to estimate the conditional probability of compliance, lead-
ing to consistent estimators of causal effects. An interesting question is whether the
estimators proposed in this dissertation can be advantageous even if the compliance
is measured without error. As we briefly discussed in Chaper 3, when all conditional
expectations are known, the CURE estimator is more efficient asymptotically than tra-
ditional IPCW. In most cases, however, the expectations must be estimated from the
data, and any possible efficiency gains due to the CURE estimator come at the cost
of needing additional modeling assumptions. A thorough investigation of the costs and
benefits of the proposed estimators when compliance is measured without error could
be useful here. In addition, we considered a point exposure study with a single outcome
for simplicity, but development of longitudinal extensions of the CURE estimator is a
natural direction for future work. Although it seems clear that a longitudinal extension
could be developed in the case where biomarkers and outcomes are available simultane-
ously, it is less clear how to deal with the more realistic situation where biomarkers are
only available at limited time points. For example, in the CENIC-p1 trial, biomarkers
of nicotine exposure were collected at baseline and at weeks 2 and 6, whereas cigarette
consumption was collected daily for the entire 6-week study. It is not immediately clear
how a longitudinal extension could be implemented that makes use of all outcome data
when only limited biomarker data are available. Restricting analyses to time points
with complete biomarker-outcome pairs is not ideal, because this would discard out-
come data from other time points, but modifying the estimators in Chapters 3 and 4 to
accommodate limited biomarker data is not trivial. This is an area that merits further
investigation.
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Appendix A
Chapter 2 Appendix
A.1 Notation
T ∗(∞): potential survival time from listing if a patient were to never receive a trans-
planted organ
T ∗(b, q): potential survival time from listing if a patient received an organ b days after
listing with organ characteristics q
Q: the set of all donor characteristics
X∗(b) the covariates collected b days after listing for a random patient including whether
or not the patient had been previously transplanted and had previously died prior to
time b
Li: calendar date the ith patient is listed for organ transplantation
N∗ij(t, q): indicator that patient died on the jth study day if she accepted an organ with
characteristics q, t days after listing
Y ∗ij(t, q): indicator that patient was at risk of death on the jth study day if she accepted
an organ with characteristics q, t days after listing
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N∗ij(∞): indicator that patient died on the jth study day if she were to never receive a
transplant
Y ∗ij(∞): indicator that patient was at risk of death on the jth study day if she were to
never receive a transplant
g: a transplant regime dictating which organs should be avoided
G: the set of all possible treatment regimes
T ∗i (g, g
′): the time from listing a patient would live if she where to follow regime g and
all other patients were to follow g′
B(g,g
′): time from listing until transplantation for a patient who follows regime g while
all other patients follow regime g′
Q(g,g
′): vector of the transplanted organ characteristics for a patient who follows regime
g while all other patients follow regime g′
Pi: the set of potential outcomes for the ith patient
fT ∗(g,g′)(t): the density of T
∗(g, g′)
fT ∗(B,Q)|X∗(b) {t|x(b)}: the conditional density of T ∗(b, q)
ρ(g,g
′) {b, q|x(b)}: the probability of receiving a transplant b days after listing with organ
characteristics q given she is untransplanted b−1 days after listing with covariate history
x(b) and the patient follows regime g while all others follow regime g′
f
(g,g′)
T,Q|X∗(t) {t, q|x(t)}: the probability of receiving a transplant t days after listing with
organ characteristics q if the patient follows regime g while all others follow regime g′
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fX(b): the density of X(b)
Ti: the observed time from entering the waiting list until death
Xij : the vector of covariates collected on the ith patient on the jth day
Nij : indicator for whether patient died on the jth study day
Yij : indicator for whether patient was at risk for death on the jth study day
Sj : number of organs available on the jth study day
Qjk: characteristics of the kth organ on the jth day
Aijk: indicator for whether the patient was transplanted with the kth organ on the jth
day
Oijk: indicator for whether the patient was offered the kth organ on the jth day
Eijk: the collection of all information on the ith subject at the time of the kth transplant
on the jth day but excluding whether the ith patient actually receives the kth organ
E·jk: the collection of information on all subjects i = 1, . . . , n prior to assigning the kth
organ on the jth study day
Rijk: the rank of the ith patient on the waiting list for the kth organ on the jth day of
the study
Dijk(g,Eijk): indicator for whether or not the kth organ on day j should be avoided
under regime g based on the organ and patient characteristics
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pi
A(g)
ijk (Eijk): the probability that the ith patient accepts the kth organ on the jth day
if the patient is complying with or following regime g.
∅: the transplant regime where patients make no changes to their propensity to accept
or decline organs
pi
A(∅)
ijk (Eijk): the probability that the ith patient accepts the kth organ on the jth day
if the patient makes no changes to her organ acceptance policy.
pi
O(g,g′)
ijk (E·jk): the conditional probability the ith patient is offered the kth organ on
day j given that she is following regime g and all other patients are following regime g′
pi
(g,g′)
ijk (aijk, E·jk): the probability that ith person receives and does not receive if aijk = 1
and aijk = 0, respectively, the kth available organ on the jth day given all information
up until the time of assigning that organ, assuming the ith patient is following regime
g and all other patients are following regime g′.
pi
(g,g′)
ij (aij , EjSj ): the probability that the ith patient has her treatment history through
study day j given that she is following regime g and all other patients follow regime g′
Sr(g, g
′): the survival probability r days after entering the waiting list for following
regime g while all other patients follow regime g′
λt(g, g
′): the discrete-time hazard of death t days after entering the waiting list for
a randomly selected patient if she were to following regime g and all other patients
followed regime g′
λPTt : the post-transplantation discrete-time hazard of death t days after transplantation
A.2 Additional Application Tables
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Table A.1: Lung Quality Model Coefficient Estimates and 95% Confidence Intervals
Coefficient Estimate 95% C.I.
Patient Age -0.029 (-0.041, -0.017)
Patient Age′ 0.041 ( 0.026, 0.056)
Patient Age′′ -0.320 (-0.566, -0.073)
Donor Age 0.000 (-0.017, 0.017)
Donor Age′ -0.045 (-0.143, 0.052)
Donor Age′′ 0.098 (-0.069, 0.265)
LAS 0.049 ( 0.015, 0.084)
LAS′ -0.985 (-1.846, -0.124)
LAS′′ 1.565 ( 0.175, 2.954)
I(Donor Diabetes = Y) 0.257 ( 0.103, 0.411)
I(Disease Group = B) 0.204 (-0.020, 0.427)
I(Disease Group = C) -0.219 (-0.433, -0.006)
I(Disease Group = D) -0.126 (-0.253, 0.000)
I(Single-Lung Transplant) 0.115 ( 0.023, 0.207)
I(Patient on Life Support) 0.441 ( 0.278, 0.604)
I(Donor Race = other) -0.199 (-0.323, -0.074)
I(Donor Race = white) -0.269 (-0.368, -0.170)
Patient-Donor Height Difference -0.003 (-0.017, 0.011)
Patient-Donor Height Difference′ -0.024 (-0.073, 0.026)
Patient-Donor Height Difference′′ 0.104 (-0.071, 0.280)
Patient BMI 0.012 ( 0.002, 0.022)
Coefficient estimates from the Cox proportional hazards model used to estimate
donor quality. Coefficients for the restricted cubic spline bases are indicated by ′
and ′′.
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Table A.2: Logistic Regression Model Coefficients and 95% Confidence Intervals For
Accepting a Transplantation.
Coefficient Estimate 95%C.I.
Intercept 0.649 (-0.190, 1.488)
Current Age -0.025 (-0.034, -0.017)
Current Age′ 0.055 ( 0.043, 0.067)
Current Age′′ -0.469 (-0.583, -0.355)
LAS 0.029 ( 0.006, 0.052)
LAS′ -0.046 (-0.426, 0.334)
LAS′′ 0.062 (-0.587, 0.711)
Days on Waiting List -0.008 (-0.009, -0.007)
Days on Waiting List′ 0.149 ( 0.118, 0.179)
Days on Waiting List′′ -0.211 (-0.255, -0.167)
Disease Group = B -0.967 (-1.099, -0.834)
Disease Group = C -0.289 (-0.414, -0.164)
Disease Group = D -0.614 (-0.686, -0.542)
Height Difference 0.103 ( 0.096, 0.111)
Height Difference′ -0.317 (-0.338, -0.295)
Height Difference′′ 0.863 ( 0.749, 0.976)
I(Donor Smoker ≥ 20 pack-years) -0.227 (-0.302, -0.151)
I(Donor Age > 50) -1.669 (-2.378, -0.961)
Current Age · I(Donor Age > 50) 0.028 ( 0.007, 0.048)
Current Age’ · I(Donor Age > 50) -0.002 (-0.034, 0.029)
Current Age” · I(Donor Age > 50) 0.015 (-0.266, 0.295)
Coefficient estimates from the logistic model used to estimate the probability of
accepting an offered organ. Coefficients for the restricted cubic spline bases are
indicated by ′ and ′′.
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B.2 Directed Acyclic Graph assumed in Simulation and
Application
Figure B.1 shows one possible Directed Acyclic Graph (DAG) for the CENIC-p1 data
and other possible applications. The arrows between B and Y are dashed because
CENIC-p1 is a unique trial in that the DAG has the causal relationship Y → B, i.e.,
the outcome, the number of cigarettes smoked, causes the biomarker, TNE. The arrow
from X to B is dotted because, in our simulation and application, we assume that
this arrow does not exist; if this arrow is removed, the DAG implies that X and B
are conditionally independent given A, Y and C. This simplifies the estimation of the
conditional density of B given A,B,X, and Y , but we note that this is assumption is
not required for the method in general.
In contrast, the DAG in many clinical trials would have B → Y . For example, in a
clinical trial investigating blood pressure-lowering medication, we might expect that B,
the circulating levels of medication or a metabolite, would cause the amount of decrease
in blood pressure Y . In this case, it may be more intuitive to model the conditional
density of Y given A,B,X,D,C and Pr(C = 1|A,B,X,D) in estimating the numerator
of the weights.
We also note that in some scenarios, it may be reasonable to assume that confounders
X or the response Y cause the subject to report compliance honestly, H. The proposed
method still provides consistent estimation of the causal effect.
A
B
C
D
H
XY
Figure B.1: A Possible Directed Acyclic Graph (DAG) for the CENIC-p1 Data
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B.3 Additional Application Tables
Table B.1: Estimated mixture distribution coefficients and parameters
Component γˆ0 γˆ1 σˆ
Compliant (C = 1) 0.12(-0.96, 1.19) 0.02(-0.01, 0.07) 0.89(0.55, 1.34)
Non-compliant (C = 0) 3.33(2.79, 4.13) 0.01(-0.04, 0.04) 0.78(0.51, 1.13)
Estimated mixture distribution coefficients and parameters (95% bootstrap per-
centile intervals) assuming B|Y,C,D = 1 ∼ N(γ0 + γ1Y, σ2). B = log(TNE), Y =
study cigarettes smoked per day.
Table B.2: Estimated coefficients for the mixture distribution logistic model Pr(C =
1|A = 1, X, Y,D = 1)
Coefficient Estimate 95% CI
Intercept 1.261 (-2.396, 14.724)
Age 0.017 (-0.031, 0.083)
Baseline log(TNE) -0.944 (-3.642, -0.440)
Baseline Cigarettes per day -0.011 (-0.188, 0.222)
Max Symptoms Week 1 0.027 (-0.088, 0.153)
MNWS Week 5 0.086 (-0.081, 0.292)
QSU Study Cigarettes Week 5 0.045 (-0.021, 0.314)
QSU Usual Brand Cigarettes Week 5 -0.048 (-0.219, -0.005)
CES Satisfaction Week 5 0.202 (-0.469, 0.846)
Y (Study Cigarettes per day) -0.004 (-0.251, 0.116)
Estimated coefficients and 95% bootstrap percentile confidence intervals for the mix-
ture distribution logistic model Pr(C = 1|A = 1, X, Y,D = 1). MNWS: Minnesota
Nicotine Withdrawal Scale, higher scores indicating greater withdrawal symptoms.
QSU: Questionnaire of Smoking Urges, higher scores indicating greater urges. CES:
Cigarette Evaluation Scale, higher scores indicating greater satisfaction with study
cigarettes.
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Table B.3: Estimated coefficients for logistic model for denominator of weights
Coefficient Estimate 95% CI
Intercept -0.707 (-4.092, 5.104)
Age 0.022 (-0.029, 0.082)
Baseline log(TNE) -0.475 (-1.698, 0.042)
Baseline Cigarettes per day -0.059 (-0.205, 0.022)
Max Symptoms Week 1 0.013 (-0.087, 0.123)
MNWS Week 5 0.050 (-0.109, 0.230)
QSU Study Cigarettes Week 5 0.013 (-0.063, 0.127)
QSU Usual Brand Cigarettes Week 5 -0.030 (-0.144, 0.009)
CES Satisfaction Week 5 0.418 (-0.216, 1.043)
Estimated coefficients and 95% bootstrap confidence intervals for logistic model
for denominator of weights. MNWS: Minnesota Nicotine Withdrawal Scale, higher
scores indicating greater withdrawal symptoms. QSU: Questionnaire of Smoking
Urges, higher scores indicating greater urges. CES: Cigarette Evaluation Scale,
higher scores indicating greater satisfaction with study cigarettes.
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B.4 Measurement Error in Y
Throughout the Chapter 3 we assumed that correctly or incorrectly reporting com-
pliance has no effect on the self-reported outcome, that is, i.e. D does not affect Y .
We note that many clinical trials rely on self-reported compliance but use endpoints
which are direct physiologic measures or adjudicated clinical events. For example, in
CENIC-p1, ITT estimates of the effect of nicotine level on other physiologic endpoints
including expired carbon monoxide were included in the primary analysis (Donny and
others, 2015).
Furthermore, under very plausible assumptions concerning the self-reported error of
cigarette consumption, we can still obtain consistent estimators of the causal effect. In
particular, assume that Y is the outcome without any self-report or measurement error
and we are interested in estimating E{Y ∗(a, 0)}, the average effect if possibly contrary
to fact all subjects were assigned treatment group a, fully complied with the assigned
treatment, and there was no measurement error in the response. Instead of observing
Y directly, we observe W = Y + , where  is the self-report or measurement error. In
this case, the CURE estimator becomes
n∑
i=1
E (Ci|Ai, Bi, Xi, Di,Wi)
E (Ci|Ai, Xi) {Wi − µ(a, 0)} I(Ai = a) = 0.
Note that this is a mean-zero estimating function provided that E (i|Ci = 1, Xi) =
0. That is, among compliers, the self-reported error is not systemic at all levels of the
confounders. As in the main paper, for simplicity we consider only a single-arm trial
with a = 1 for all participants, but the results easily generalize to multi-arm trials.
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E
[
E (Ci|Bi, Xi, Di,Wi)
E (Ci|Xi) {Wi − µ(1, 0)}
]
= E
[
Ci
E (Ci|Xi) {Yi + − µ(1, 0)}
]
= E
[
Ci
E (Ci|Xi) {Yi − µ(1, 0)}+
Ci
E (Ci|Xi)i
]
= 0 + E
[
Ci
E (Ci|Xi)E (i|Ci, Xi)
]
= E
[
Ci
E (Ci|Xi)E (i|Ci = 1, Xi)
]
= 0.
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C.1 Additional simulation results: no participants with
known compliance status
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C.2 Additional Application Tables
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Table C.7: Estimated coefficients for the logistic model Pr(C = 1|X,Y ) (CURE Esti-
mator) and Pr(C = 1|X) (CURE+ estimator)
Coefficient CURE Estimator CURE+ Estimator
Intercept 1.26(-1.92, 6.12) 1.15(-1.92, 6.22)
Age 0.02(-0.03, 0.07) 0.02(-0.02, 0.06)
Baseline log(TNE) -0.94(-2.08, -0.46) -0.94(-2.14, -0.42)
Baseline Cigarettes per day -0.01(-0.17, 0.14) 0.03(-0.12, 0.10)
Max Symptoms Week 1 0.03(-0.07, 0.12) 0.03(-0.07, 0.12)
MNWS Week 5 0.09(-0.05, 0.25) 0.11(-0.05, 0.27)
QSU Study Cigarettes Week 5 0.05(-0.02, 0.15) 0.07(-0.02, 0.17)
QSU Usual Brand Cigarettes Week 5 -0.05(-0.14, -0.01) -0.06(-0.15, -0.00)
CES Satisfaction Week 5 0.20(-0.29, 0.68) 0.10(-0.35, 0.69)
$Y$ (Study Cigarettes per day) -0.00(-0.15, 0.11) −
Estimated coefficients (95% bootstrap percentile intervals) for the logistic model
Pr(C = 1|X,Y ) (CURE Estimator) and Pr(C = 1|X) (CURE+ estimator) es-
timated as part of the mixture density (i.e., estimated for the numerator of the
weights).
120
T
ab
le
C
.8
:
E
st
im
at
ed
co
effi
ci
en
ts
an
d
p
ar
am
et
er
s
fo
r
th
e
li
n
ea
r
m
o
d
el
fo
r
Y
|X
,C
C
U
R
E
+
E
st
im
at
or
W
-R
E
G
E
st
im
a
to
r
C
o
effi
ci
en
t
C
=
1
C
=
0
C
=
1
In
te
rc
ep
t
-1
1.
57
(-
23
.9
9,
0.
51
)
-0
.5
7(
-1
5.
36
,
7.
51
)
-1
0.
60
(-
24
.5
9
,
2
.1
3
)
A
ge
0.
08
(-
0.
07
,
0.
33
)
0.
09
(0
.0
0,
0.
21
)
0.
11
(-
0.
09
,
0
.3
4
)
B
as
el
in
e
lo
g(
T
N
E
)
-0
.1
6(
-4
.5
2,
2.
74
)
-0
.5
5(
-2
.3
8,
0.
87
)
-0
.5
9(
-5
.0
0,
2
.8
8
)
B
as
el
in
e
C
ig
ar
et
te
s
p
er
d
ay
1.
58
(0
.4
8,
2.
08
)
0.
86
(0
.7
5,
1.
54
)
1.
41
(0
.5
9,
2.
0
9
)
M
ax
S
y
m
p
to
m
s
W
ee
k
1
-0
.0
1(
-0
.5
7,
0.
32
)
-0
.0
9(
-0
.2
7,
0.
23
)
-0
.1
0(
-0
.5
4,
0
.3
3
)
M
N
W
S
W
ee
k
5
-0
.2
9(
-0
.8
6,
0.
43
)
-0
.2
7(
-0
.6
1,
0.
30
)
-0
.2
7(
-0
.8
9,
0
.3
8
)
Q
S
U
S
tu
d
y
C
ig
ar
et
te
s
W
ee
k
5
0.
01
(-
0.
37
,
0.
43
)
-0
.0
6(
-0
.2
0,
0.
17
)
-0
.0
6(
-0
.3
8,
0
.3
6
)
Q
S
U
U
su
al
B
ra
n
d
C
ig
ar
et
te
s
W
ee
k
5
0.
01
(-
0.
30
,
0.
38
)
0.
09
(-
0.
09
,
0.
18
)
0.
07
(-
0.
29
,
0
.3
9
)
C
E
S
S
at
is
fa
ct
io
n
W
ee
k
5
1.
26
(-
0.
67
,
4.
19
)
0.
52
(-
0.
45
,
1.
71
)
1.
69
(-
0.
82
,
3
.8
7
)
E
st
im
at
ed
co
effi
ci
en
ts
an
d
p
ar
am
et
er
s
(9
5%
b
o
ot
st
ra
p
p
er
ce
n
ti
le
in
te
rv
al
s)
fo
r
th
e
li
n
ea
r
m
o
d
el
fo
r
Y
|X
,C
es
ti
m
at
ed
as
p
ar
t
of
th
e
m
ix
tu
re
d
is
tr
ib
u
ti
on
(C
U
R
E
+
es
ti
m
at
or
)
or
u
si
n
g
w
ei
gh
ts
Eˆ
(C
|B
,X
,Y
)
(W
-R
E
G
es
ti
m
at
or
).
C
=
1
in
d
ic
at
es
th
e
co
m
p
on
en
t
d
en
si
ty
fo
r
co
m
p
li
er
s,
C
=
0
in
d
ic
at
es
th
e
co
m
p
on
en
t
d
en
si
ty
fo
r
n
on
-c
om
p
li
er
s.
C
=
0
is
m
is
si
n
g
fo
r
th
e
W
-R
E
G
es
ti
m
at
or
b
ec
au
se
th
e
es
ti
m
at
or
on
ly
re
q
u
ir
es
co
effi
ci
en
ts
fo
r
C
=
1.
121
Table C.9: Estimated coefficients for the logistic model Pr(C = 1|X)
Coefficient CURE Estimator CURE+ Estimator
Intercept -0.71(-3.72, 4.64) -0.89(-4.05, 4.64)
Age 0.02(-0.03, 0.08) 0.02(-0.03, 0.08)
Baseline log(TNE) -0.47(-1.63, 0.03) -0.39(-1.63, 0.05)
Baseline Cigarettes per day -0.06(-0.17, 0.02) -0.03(-0.18, 0.04)
Max Symptoms Week 1 0.01(-0.08, 0.12) 0.01(-0.08, 0.12)
MNWS Week 5 0.05(-0.10, 0.22) 0.05(-0.10, 0.22)
QSU Study Cigarettes Week 5 0.01(-0.06, 0.12) 0.02(-0.06, 0.12)
QSU Usual Brand Cigarettes Week 5 -0.03(-0.13, 0.01) -0.04(-0.13, 0.01)
CES Satisfaction Week 5 0.42(-0.13, 1.00) 0.36(-0.17, 1.04)
Estimated coefficients (95% bootstrap percentile intervals) for the logistic
model Pr(C = 1|X), the denominator of the weights
